Helping Women Use the Pill
Around the world over 100 million women rely on oral contraceptives (OCs). They benefit from the effectiveness, safety, and convenience of the pill. Still, many women do not use the pill as successfully as possible. Programs can help women use OCs effectively.
When taken properly, the pill is a highly effective contraceptive. Oral contraceptives are unique among family planning methods, however: Their full effectiveness requires the user’s daily action. In part because some women have trouble taking the pill correctly, pregnancy rates are usually much higher than if the pill were used perfectly.
For combined OCs the perfect-use pregnancy rate is estimated at only 0.1 per 100 women in the first 12 months of use. In actual use pregnancy rates range from 1.7 to 10.5 pregnancies per 100 women in the first 12 months in 21 surveyed countries.
Better pill use would make a big difference. Based on worldwide levels of pill use in 2000, for example, over 2 million women become pregnant unintentionally each year because they do not take the pill effectively. Also, women would be healthier, and medical costs would be less, since complications of pregnancy, childbirth, and unsafe abortion are among the leading causes of women’s ill health and death in developing countries.
Encouraging more effective OC use requires understanding problems with pill-taking. OC users make a variety of mistakes. These include missing pills, taking “rests” from pill use, starting the next pill pack too late, and taking pills out of sequence. Research suggests that most pregnancies during pill use result from increasing the number of days between pill packets that hormonal pills are not taken. Errors sometimes occur because women are not told how to use the pill, or they receive incorrect advice. Some users do not understand or remember instructions.
Some pill users who become pregnant report vomiting or diarrhea and/or use of antibiotics around the time of conception. It is not clear what role these events play in pill failure.
What Can Be Done?
The better women understand the pill, the better they can use it effectively and continue using it. Women need to know how the pill works, how to take it correctly, what to do if they miss pills, how to deal with common side effects, and what symptoms indicate the need to see a doctor or nurse.
Using mass media. Radio, television, and other mass media can inform potential users, users, and their partners about the pill and other methods. The mass media often start people thinking about family planning and contraceptives. They also can remind continuing users about effective pill use and help to counter false rumors about the pill.
Counseling. Counseling–face-to-face dialogue between client and provider–improves OC use. Women who receive good counseling are more likely to continue using the pill and to use it effectively. In particular, women need to know about the common side effects before they start the pill. Counseling is especially helpful both when a client is deciding about the pill and if she experiences side effects in the first months of use. Providers counsel better when trained and enabled to use both knowledge of family planning and communication skills.
New guidelines, new attitudes. Family planning programs help clients use OCs more successfully when they update guidelines and procedures to reflect new scientific understanding about OCs. Unnecessary legal, medical, or other institutional barriers sometimes impede pill use. Such barriers include baseless eligibility restrictions, unnecessary screening procedures, and legal, programmatic, and provider bias against certain family planning methods or groups of clients. By adopting guidelines, procedures, and attitudes that respond, first and foremost, to clients’ needs and wishes, family planning programs can help pill users find more satisfaction and more value in their contraceptive method.
Improving access. Making it easier to obtain OCs helps women use them correctly without interruption. Ensuring regular supplies, making pills affordable, and offering them conveniently all are important. Without good access, women may discontinue, take pills inconsistently, or switch to less effective methods. Convenient clinics, community-based distribution, social marketing, links with other health services, and good supply chains can make it easier for women to use the pill.
Using Oral Contraceptives
Oral contraceptives (OCs) are an effective family planning method that over 100 million women around the world are using. Many more have used OCs at some time in their lives. (See Population Reports, Oral Contraceptives: An Update, Series A, No. 9, Spring 2000.)
Particularly because so many couples rely on the pill, ensuring its effective use is important to fulfilling people’s reproductive goals. OCs are unique among contraceptives in that their full effectiveness requires the user’s daily action. No other method requires the user to act on a daily basis, even when no sexual contact takes place.
When taken consistently and correctly, OCs are one of the most effective methods. In actual use, however, OCs are not as effective at preventing pregnancy as they could be. If family planning programs and health care providers paid greater attention to helping women use the pill, the actual effectiveness of OCs could improve substantially.
Strategies to improve pill use include giving women complete and easily understood information, providing individual counseling, and offering frequent follow-up messages to remind women about effective pill use. Mass media campaigns that inform people about family planning can foster social approval of it and educate people about available methods. Making pills accessible and removing any unnecessary restrictions to their safe use also can help women use the pill more effectively.
OC Pregnancy Rates
The gap between perfect-use pregnancy rates and typical-use pregnancy rates among OC users suggests that many women do not use OCs effectively. Perfect-use pregnancy rates reflect only the inherent technical failure of a method if it is used perfectly–both consistently, and correctly–and if users do not stop using it for any reason. In contrast, typical-use pregnancy rates reflect how often pregnancy occurs as the method is commonly used in a population (223).
For combined OCs, which contain both progestin and estrogen, the perfect-use pregnancy rate is estimated at just one pregnancy per 1,000 women, or 0.1 per 100, in the first 12 months of use. For the progestin-only pill, the perfect-use pregnancy rate is estimated at five pregnancies per 1000 women, or 0.5 per 100, in the first 12 months of use (223).
Typical-use pregnancy rates for OCs(*) are generally much higher. National surveys in 21 countries found that typical-use pregnancy rates among OC users ranged from 1.7 pregnancies per 100 women in Bangladesh to 10.5 per 100 women in Bolivia in the first 12 months of use (see Figure 1). In the US the pregnancy rate among OC users in 1995 was 6.9 per 100 women over 12 months (225).
[Figure 1 ILLUSTRATION OMITTED]
Longer-term users of OCs tend to be more effective users, possibly both because of experience and because less successful users have become pregnant, discontinued use, or switched to a different method. In five of seven countries with data for 24 months of pill use, pregnancy rates were lower in the second year than in the first year (4, 225). Over two years, rates ranged from 4.5 pregnancies per 100 OC users in Thailand to 16.5 pregnancies per 100 OC users in Egypt (4).
While some typical one-year pregnancy rates may seem modest, even low levels of contraceptive failure each year can mean that over the long term many women will have unintended pregnancies. If the pregnancy rate for the pill is 6% per year among a group of pill users, for example, nearly half would experience unintended pregnancy within 10 years (184). Over 18% of users would become pregnant after 10 years at a 2% pregnancy rate per year, while an annual pregnancy rate of 10% would result in 65% of users experiencing unintended pregnancy over 10 years.
Based on estimates of worldwide pill use for 2000, in one year at least 2 million women become pregnant unintentionally because they do not take the pill effectively (see box, p. 8). If even just 1 more woman in every 10 used OCs effectively, there would be 200,000 fewer unintended pregnancies.
As typically used, the pill is less effective in preventing pregnancy than such other reversible methods as intrauterine devices (IUDs) and injectables. Yet, if used perfectly, the pill would be among the most effective methods–slightly more effective than the copper T IUD, progestin-only injectable contraceptives, and female sterilization. In fact, only Norplant implants have an expected perfect-use failure rate lower than that of combined OCs (223).
Common Problems with Using the Pill
Many individual and social factors can interfere with women’s correct and consistent use of OCs: fear of health risks, cost, side effects, lack of confidence in the effectiveness of the method, and social disapproval of OCs or of family planning itself (166). Lack of knowledge about how to use the pill and how to manage lapses in pill-taking also contributes to ineffective pill use.
Pill-taking mistakes are not unique to OC users. Research on medication-taking habits for a number of illnesses–from epilepsy to asthma–indicates that 10% to 20% of patients have trouble taking correct doses, whether they underuse, overuse, or use their medications inconsistently (146).
Common problems with OC use include missing pills, taking “rests” from pill use, running out of pills, incorrectly switching from one pill packet to the next and so extending the amount of time without taking hormonal tablets, and taking pills out of sequence. Family planning programs can address many of these problems.
Missing pills. Many women may miss a few pills in a packet and not take corrective action. Sometimes women simply forget to take a pill now and then. Some women may miss a few pills because their supply runs out or because they leave their pills at home when they travel. Women may skip pills because they are experiencing side effects, such as nausea or spotting, and think–mistakenly–that skipping a few pills will reduce these side effects.
Missing a pill now and then seldom leads to pregnancy. Frequently missing a number of pills, however, increases a woman’s chances of becoming pregnant. Furthermore, missing pills in each pack without becoming pregnant can be self-reinforcing. Some women who miss pills may begin to think that their irregular pill-taking pattern is good enough to avoid pregnancy and thus continue taking the pill haphazardly (129, 165).
Eventually, some women will lose this gamble. A study in Western Europe, for example, found that women who usually missed one or more pills from each packet were nearly three times more likely to become pregnant than women who reported not missing any pills (182).
Although missing pills increases a woman’s risk of unintended pregnancy, women who do not use the pill perfectly still have a lower overall risk of pregnancy than women who use no contraception at all. In a US study only 13% of pill users took their pills correctly over a period of 6 to 12 months. Nevertheless, the pill users overall experienced only one-third the rate of pregnancy that occurred among women who had obtained pills but did not use them at all (148).
Women can benefit from instructions on how to make up missed pills. Women who miss one pill should take the missed pill as soon as they remember. Women missing two or more pills can protect themselves from pregnancy by following the “seven-day” guideline (see box).
Few studies have looked at what corrective action women take when they miss pills. A 1997 study of 103 US women’s pill-use habits over three cycles found that 52% did not miss more than one pill. Among women missing more than one pill, some 18% avoided intercourse for a week thereafter, while 3% used a back-up method for seven days after missing pills. Either abstinence or a back-up method would be effective if kept up until a woman had taken hormonal pills for seven days straight. Some 27%, however, did not take any protective action after missing multiple pills (147).
Taking “rests” from pill use. Sometimes women stop taking their pills temporarily. Some health care providers incorrectly advise pill users that they need to give their bodies a “rest period” from the pill. For example, a 1993 study in Jamaica found that two-thirds of private providers recommended a rest from pill use in order to “expel” chemicals from the body (80).
Many women also believe that they need to give their bodies a rest from the pill. In an Egyptian study 13% of self-identified pill users who had no pills on hand when interviewed said that they were resting from the pill hormones. Nearly 20% of women with pill packets at home at the time of interview reported not taking a pill in the last eight or more days because they were resting from the method (129). In Australia some 27% of OC users interviewed reported taking a rest from pill use at some time (237).
Resting from the pill is a common practice around the world, and yet there is no scientific justification for it. There is no accumulation of hormones in the body when taking OCs (55,220). Nor are there any known health or fertility benefits to taking periodic rests. In contrast, the risks can be considerable. In one study 25% of women who took such rests from pill use became pregnant unintentionally (75).
Making transition errors. Some pill users do not begin a new pill packet at the right time (94, 123, 164, 212). Making this kind of mistake–a transition error–is common. In Bangladesh, for example, although most women correctly answered questions about how to take pills and how to make up for missed pills, only 37% of rural users and 24% of urban users knew when to begin their next 28-day packet (123). The 28-day pill packets allow users to take a pill every day, rather than having to count seven pill-free days before starting a new 21-day packet. It would seem that taking a pill every day would be easier to remember than counting days between cycles. Nevertheless, a study in Egypt found that users of 21- and 28-day packets made transition errors equally often (94).
Some women incorrectly wait for a withdrawal bleed, which they perceive as menstruation, before starting the next pill packet. In Bangladesh, for example, 47% of rural woman and 59% of urban women surveyed said that they waited for evidence of menstruation between pill packets (123). Women with misperceptions about the pill–in particular, the incorrect idea that OCs can cause infertility (1, 150)–may wait for what they think is a menstrual period as evidence that the pill has not affected their ability to have children (100). This misperception can extend the interval between pill packets. The correct practice is to start the next cycle of pills on schedule–no later than seven days after the last hormonal tablet–regardless of when withdrawal bleeding does or does not occur.
Taking pills out of sequence. Some women do not take their pills in the correct order. Rather than follow the arrows on the packet that indicate which pill to take next, some women take pills in random order or follow the rows in a different direction. A study in Egypt found that 24% of women who could show the interviewer their pill packets had taken pills out of sequence, while in Indonesia 5% had made this mistake (94). With 28-pill packets, taking pills out of sequence can result in taking placebo pills at the wrong time in the pill cycle, increasing the risk of pregnancy.
Who Uses Pills Incorrectly?
Any woman, regardless of her education, literacy, or socioeconomic status, can misunderstand or forget pill instructions. The mix of factors that influence how women take the pill varies considerably within and among countries (86, 94).
Level of education, household income, and other social factors can strongly predict effective pill use in one country but not in another (33, 94, 123, 139). In Egypt, for example, a study observed that inability to read was a good predictor of improper pill use. In Botswana and Zimbabwe, however, the same study could not identify any set of indicators that consistently identified women who use the pill incorrectly (94).
Some studies have found that younger women–adolescents, in particular–are less likely than older users to take the pill correctly (89, 94, 163). Other studies, however, have found no consistent association between age and proper OC use. Age often acts as a surrogate for other factors that influence pill use, such as education, motivation, side effects, and the client’s perception of the quality of the provider-client interaction (178, 182).
Motivation to avoid pregnancy is important to effective pill use. Women who are sure that they do not want any more children typically are more effective pill users than women who do not currently desire pregnancy but who want more children in the future. In the Philippines, for example, older women, women with many children, and women using contraception to limit rather than space births had the lowest rates of pregnancy among all pill users (153).
Consequences of Pill Failure
Pill failures can pose adverse consequences for women’s health and for societies and economies. Unplanned pregnancies and unwanted childbearing can impose heavy economic burdens on women and their families and foreclose opportunities (132). Complications associated with pregnancy, childbirth, and unsafe abortion are among the leading causes of death and disability among women of reproductive age in developing countries (144, 211). Pregnancy-related injuries include infertility, impaired mobility, severe anemia and chronic weakness, pelvic pain, uterine rupture, and fistula (53, 229).
For many women throughout the world, effectively using family planning can save not only their own lives but also their children’s. The one million or more children who are left motherless each year due to maternal mortality are 3 to 10 times more likely to die within two years than children who live with both parents (229).
Some women who become pregnant while taking the pill have abortions. In England 17% of abortion-seekers were using the pill when they became pregnant (173). In Australia a survey of over 2,000 women who had abortions in 1992 found that 14% were using the pill when they conceived (235). Where abortion is unsafe, its consequences include nearly 80,000 maternal deaths annually and hundreds of thousands of disabilities. In fact, in some countries complications of unsafe abortion causes more maternal deaths than any other single factor (243). More effective pill use can avert much morbidity and mortality among women of reproductive age.
Continuation and Switching
Women stop using the pill for various reasons. Some want to become pregnant. Others no longer need contraception. Still others may shift to another method that better meets their changing family planning needs. Many women, however, stop using the pill but do not switch to another method at once even though they remain sexually active and do not want to become pregnant. Some of these women remain unprotected for months, and a great many of them become pregnant (see box).
If the percentage of women who stopped pill use without switching to another method while still in need of contraception was reduced by one percentage point, 620,000 unintended pregnancies could be avoided each year.
Continuation rates measure the number of contraceptive users, per 100 initial users, who are still using the same method a given length of time after they started, usually in 12 month increments. In general, continuation rates for pills–and for injectables and condoms–are lower than for IUDs and implants. A user can easily stop using pills, injectables, or condoms on her own, but she usually must seek out a health care provider to have an IUD or implants removed.
Oral contraceptive continuation rates differ greatly among countries and programs. In 8 of 10 countries with available survey data, about two-thirds or fewer pill users continued OC use for 12 months or more, and half or fewer continued to use the pill for at least two years (see Figure 3). By comparison, in 7 of 9 countries with comparable data, two-thirds or more of IUD users continued using the IUD after two years (4, 58, 139, 153,225).
[Figure 3 ILLUSTRATION OMITTED]
Family planning programs often can help more women achieve their reproductive intentions if they focus on serving women already using a method rather than only on attracting new users (102). As contraceptive use becomes more widespread, continuing users increasingly outnumber potential new users. For example, in the US, only an estimated one-fifth of nearly 19 million pill users in one year had started the pill that year (181).
Short-term versus long-term use. Some women use OCs for only a short time–an average of four to six months (62, 177). Short-term users are most likely to discontinue because of side effects such as nausea, breakthrough bleeding, spotting, weight gain, and breast tenderness (124, 139, 180, 182, 192, 193, 227).
Although a substantial group of OC users quit within a few months, many other women are long-term OC users. Data that include short-term as well as long-term users demonstrate that many women rely on the pill for the long term. For example, in the mid-1990s median duration of pill use was 18 months in the Philippines (153) and 27 months in Indonesia (58). In Zimbabwe, where most family planning users rely on the pill, the median length of OC use was 28 months (186). A 1995 Canadian survey found that the average length of pill use was seven years, and that, among pill users over age 35, nearly 70% had used the pill for more than 10 years (17).
Side effects are often the single greatest reason that women stop using the pill after only a short time. In Bangladesh, for example, of the 45% of pill users who discontinued within a year, half discontinued because of side effects. Far fewer discontinuers–only 16%–stopped to become pregnant. Reasons such as husband’s disapproval, availability, cost, desire for a more effective method, convenience, and health concerns about the pill accounted for 13% of pill discontinuation (139). Similarly, side effects were the reason that over half of the women gave for discontinuing pill use in Ecuador, Egypt, and Tunisia after one and two years of use (4, 139, 153, 186) (see Table 1).
Table 1 Oral Contraceptive Discontinuation Rates, 1987-1994
% of All Pill Users Discontinuing and % Discontinuing Due to Side Effects, As Calculated from Findings of National Surveys
Ref. All Side All Side
Country & Year No. Reasons Effects Reasons Effects
Bangladesh 1993-94 139 45 23 61 —
Ecuador 1987-88 4 37 19(*) 55 30(*)
Egypt 1987-88 4 37 19(*) 59 31(*)
Indonesia 1994 58 33 6 47 —
Morocco 1987-88 4 35 14(*) 54 23(*)
Philippines 1993 153 39 13 56 —
Thailand 1987-88 4 36 6(*) 50 9(*)
Tunisia 1987-88 4 41 23(*) 59 36(*)
Zimbabwe 1994 186 15 2 43 —
(*) Discontinuing due to health concerns including side effects
Inconsistent pill use. How consistently women take the pill can affect the incidence of side effects. Missing pills or taking pills late can increase the occurrence of nausea, vomiting, spotting, and breakthrough bleeding (37, 124, 163, 179).
In fact, using the pill inconsistently can create a self-defeating sequence of events. For example, a woman misses a pill, causing spotting or breakthrough bleeding. She may take two pills the next day to make up for the missed pill, but this brings on nausea and perhaps vomiting. Because of these problems, she skips more pills–mistakenly thinking the break will alleviate her side effects–and so experiences more side effects. This chain of events can soon lead her to stop pill use altogether.
Many women discontinue the pill because they were not informed when they started that it can cause side effects (180, 235). When side effects are unexpected, they can be frightening. Telling pill users ahead of time about the possible common side effects and how inconsistent use can aggravate side effects are among the most important messages about pill use that providers can convey.
Breakthrough bleeding and spotting. For many women pill use makes periods more regular and reduces blood loss. Breakthrough bleeding and spotting, however, occur in some users and affect pill use, particularly when women do not understand why they are bleeding. Some women mistakenly think that irregular bleeding indicates a serious health problem, such as cancer (88, 166), and so they may stop taking the pill.
Covert pill users–that is, women using the pill without their partners’ knowledge–fear that breakthrough bleeding will reveal their contraceptive use to their partners and families. Changes in menstrual patterns, irregular bleeding, and amenorrhea are a primary concern and often the main reason for discontinuation among covert pill users (22). Islamic women, for example, cannot pray while menstruating. Not attending prayers for weeks at a time could alert husbands and members of the extended family to covert contraceptive use (22).
In cultures where women’s activities are restricted during menstruation, breakthrough bleeding amounts to far more than dealing with an unpleasant or frightening side effect. Women’s participation in food preparation, religious rituals, community events, school attendance–in general, their mobility–is severely constrained while they are menstruating (13, 134). For example, some women in India cannot touch their children during menstruation, while others are forced to sleep away from their families (77). Prolonged or frequent bleeding episodes that limit women’s everyday activities can contribute considerably to discontinuation of OC use.
The Contraceptive Coverage Gap
Some women who want to avoid pregnancy face a gap in contraceptive coverage because they stop using the pill but do not adopt another family planning method (36, 168, 180). For example, in India during a year-long study, one-fourth of women who reported discontinuing OCs for reasons other than wanting a child did not adopt another method (65). In Bangladesh, among women who stopped using the pill within an 18-month period for any reason other than desiring pregnancy, half did not adopt another method (123). Among women in the Philippines who discontinued pill use and still needed contraception, 68% did not adopt a new method within one year (153). In Zimbabwe nearly three-fourths of such discontinuers were left without protection against pregnancy for over a year (186). In the US a 1995 survey found that 20% of pill discontinuers had not adopted another contraceptive method one year after they had stopped taking the pill (225).
This gap in contraceptive coverage leads to many pregnancies, since women quickly regain their fertility after discontinuing pill use. In Ghana, for example, 53% of women who stopped coming to a health facility for OCs became pregnant within four months. Of the women who waited more than four months to return, 75% became pregnant. Nearly 40% reported these pregnancies as unintended (227).
While switching from one family planning method to another is every person’s right, it should be exercised with full knowledge, because women who switch from the pill to another family planning method can increase their risk of unintended pregnancy (36, 168, 180). An analysis of use patterns among a group of US pill users over one year, extrapolated to all US pill users, attributed 194,000 unintended pregnancies to about 1.7 million women switching from OCs to a less effective method, including condoms, diaphragms, spermicide, other barrier methods, withdrawal, and periodic abstinence (181).
Among women in the Philippines who stopped using the pill, one-fourth switched to a traditional family planning method, yet none of these women wanted another pregnancy (153). Similarly, in Bangladesh 12% of pill users switching methods or discontinuing use changed to a traditional method (139).
Women who switch from OCs to long-term or permanent methods, of course, experience far fewer unintended pregnancies than women who switch to less effective methods. For example, of nearly 880,000 pill users in the US estimated to switch from the pill to an IUD or sterilization, about 11,000 would experience unintended pregnancy (181).
Pill users often switch to the IUD, implants, or sterilization once they have had all the children they want. In Finland, for example, the pill is the most common method used by women who have no children. The IUD is used almost exclusively by women who have had at least one child, while sterilization becomes more common among contraceptive users as they have more children (117). In Sri Lanka more than twice as many pill users over 30 years old switched from the pill to sterilization than did women under age 30 (109).
Many women who stop using the pill choose the pill again later. In Ghana, among women who had discontinued pill use and later returned to the same health facility to use family planning again, half chose the pill again (227). In Peru some 30% of women who stopped using the pill of their own accord started using it again within a year (119). A study in the US found that, one month after stopping pill use, 65% of women began using contraception again. Of these, over one-fifth were again using the pill. One year after discontinuing use, 80% had resumed contraception, and again one-fifth were taking the pill (225).
How Mass Media Can Help
The more women know about the pill, the better they are able to use it. In a study of British university students, for example, women with good general knowledge about OCs were less likely to forget a pill for up to 12 hours than women who had less knowledge about OCs (231). In the Netherlands women who received detailed information about the pill used OCs more effectively at first and had more positive opinions of its medical benefits than other women (40).
Conversely, receiving less information and counseling about the pill results in poorer pill use. In a European study of over 6,500 current and past OC users, those who said they did not receive enough information about the pill nor enough help from their providers were one and one-half times more likely to miss one or more pills per cycle than women who felt they received adequate information and counseling (182).
Accurate knowledge is the key to making good decisions about one’s reproductive health. Studies show that many women are able to make decisions as well as their providers do, as long as they are given and understand the necessary information (29, 250).
While counseling is valuable, a single counseling session with a family planning provider usually cannot cover all of the information that a person needs to make an informed choice among family planning methods. Nor should counselors and other front-line health care providers have to bear all the responsibility for seeing that clients are fully informed.
One way to inform pill users, potential users, and their partners about family planning is through the mass media, including radio, TV, video, and newspapers (157). Mass media bring family planning to people’s attention even before they meet a provider and often start the decision-making process that leads people to seek family planning services (158). Because the mass media also reach continuing family planning users, they can provide important reminders about pill use.
In many developing countries the mass media have been a key way to disseminate information about family planning and to improve reproductive health behavior (156). The mass media reach many different groups, influencing family planning use among the married and unmarried, the literate and nonliterate, and men as well as women (238).
People obtain much of their information about the pill from the mass media, even though the information is not necessarily designed to aid contraceptive choice and use. In Nigeria, for example, among 500 female university students surveyed, 40% received information about the pill from newspapers or magazines, 28% from television, and 26% from radio. Some 44% reported getting pill information from their peers, 42% from providers, and 30% from nurses (1). Typically, however, information in the mass media is not detailed enough to help people choose a specific family planning method and use it effectively.
Because the mass media reach large and diverse audiences, family planning programs can use the media to improve the use of OCs and other contraceptive methods. In Nepal, for example, the Ministry of Health has used mass media to educate radio listeners about different contraceptives and their use. The radio drama, Cut Your Coat According to Your Cloth, airs four times a week and has been broadcast since 1995. This program gives detailed information on how OCs and other methods work, their advantages and disadvantages, and their proper use (104, 105).
The mass media can reach family planning providers as well as the public. Providers can keep up to date with advances in family planning through mass media distance education courses. In Nepal a weekly distance education course for health workers, Service Brings Reward, complements the radio drama for family planning users and has helped to improve the quality of provider-client interaction (104, 106, 214).
In reaching out to pill users, family planning programs, providers, and the mass media face the challenge of communicating information in ways that are accurate, effective, easy to remember, and easy to act on. In the Nepal drama, for example, messages are woven into an entertaining story line about the lives of characters. In one 15-minute episode on the pill, listeners could learn:
* How pills prevent pregnancy,
* Who are good candidates for pill use,
* Cancer prevention benefits of the pill,
* The need to take the pill every clay at the same time,
* How to make up a missed pill,
* Common side effects, and
* Where to get pills.
The program advises interested listeners to see a health worker for further information and counseling (105). The drama has a strong positive effect on listeners’ perceptions of and behavior toward family planning (214).
The pill is not the best method for everyone. The mass media need to inform people about the existing range of contraceptive choices. The more family planning options available–and the better the range of choices is known–the better each person can find the method she or he can use with satisfaction. The result will be that every contraceptive method, OCs included, will be used more effectively.
Repeat to reinforce. Repeating a message reinforces it. In a study in the Netherlands, even new pill users who at first had the best use practices began missing more pills by their third pill cycle. These women said that they referred to their audiotaped pill use instructions far less by the third cycle than at first (40). Another study on consistent pill use found women missed more pills with each subsequent pack over three months (147).
One implication of more pills being missed over time is that women may need repeated messages about effective pill use. Another is that, rather than depend solely on instructions that users must seek out, messages also need to reach people frequently and easily, as on radio and TV.
The mass media can reinforce messages on effective use in a variety of ways to maintain interest. For example, a character in a radio drama can be depicted taking her daily pill in response to a cue that reminds her. At the same time, short spots can remind listeners: “Have you taken your pill today?”
Portraying the pill accurately. How the mass media portray OCs to the public–be it accurately or inaccurately–strongly affects women’s perceptions and use of the pill. Negative portrayals in the news have caused widespread concerns over the safety of OCs and have contributed to irregular use and discontinuation (88, 235).
For example, in the UK and other European countries the mass media gave extensive publicity to reports in the mid-1990s about some types of OCs and risks of cardiovascular disease–reports whose validity continues to be debated. The publicity created a pill scare. Many women switched to other OCs or stopped taking pills altogether. One provider of legal abortions in the UK reported that 61% of women seeking abortions said they had quit taking pills in mid-pack as a result of the media coverage (43, 76). In the months following, the number of unintended pregnancies and abortions increased substantially (9, 26, 27, 101, 171, 242).
Involving men. In most of the world men have greater access to the mass media than women do, and so family planning messages in the mass media may reach men even more than women (238, 239). Often men greatly influence their partners’ family planning behavior and can help them use the pill more effectively (see box).
Counseling About the Pill
Counseling is important in helping women to use the pill effectively. Good counseling, as part of good care, improves OC use and encourages continuation (31, 178). In contrast, poor care discourages clients from continued use or returning to seek health care at all (116). Community-based distributors, staff at health posts, pharmacists–anyone giving women pills and advising on their proper use–as well as community social networks can share information and offer support to pill users (see p. 20).
Personal interaction between client and provider is the key to good counseling. To counsel women effectively, providers themselves need to know a lot about the pill, to have good interpersonal communication skills, and to work in an environment that promotes good-quality interaction and supports follow-up with clients. When family planning providers have the skills, resources, and support to be good counselors, clients make better informed decisions, use methods more effectively and longer, and make more appropriate changes among methods.
What Is Good Counseling?
Counseling is a partnership for good decision-making: The client knows best what her own family planning needs are, and the provider knows most about family planning, contraceptive methods, and other reproductive health issues (175). Exchange of information is key. The client explains her situation and needs, and the provider tailors responses to suit them (6, 38, 110, 143, 146, 175, 235).
GATHER, a six-step process, can help service providers counsel family planning clients. The letters in the word GATHER stand for Greet-Ask-Tell-Help-Explain-Return. Each step of the GATHER process covers a different element of counseling and helps guide provider-client interaction. Following these steps helps clients to make informed decisions about their family planning options (175). GATHER has been translated into at least 10 languages and adopted by training programs around the world (103). (See Population Reports, GATHER Guide to Counseling, Series J, No. 48, December 1998.)
Counseling often can help the client both choose and use a method. Most clients already have a method in mind when they meet with a provider. In this case, the provider’s responsibility is to make sure that the client’s choice is based on accurate understanding of the method and awareness of other options. The provider can help the client consider whether the method she prefers suits her own needs and situation.
Since in some places OCs are better known than other methods–almost synonymous with family planning itself–counselors may need to check especially that clients who ask for OCs are aware of other options. Also, the provider needs to check whether the client has any medical condition that would rule out use of the client’s preferred method (see checklist).
Once the client confirms her choice, the provider’s responsibility is to help her use her method effectively and with satisfaction. If a woman chooses OCs, the provider discusses how to take the pill, what to do if one or more pills are missed, what to do if common side effects occur, when and how to use back-up methods, and what symptoms indicate a need to seek immediate care from a doctor or nurse.
At the first meeting the provider needs to assure that the client’s understanding of the pill is accurate (111, 235). It usually is difficult to correct misperceptions about a contraceptive method after the client has started using it (20). Thus the first meeting should convey key messages about effective pill use (see box).
Women who receive good counseling are less likely to discontinue using the pill. In Colombia, for example, a study found that women who rated their health promoter “very effective” at communication were more likely than other women to continue using the pill (62). Other research shows that a client’s perception of the quality of interaction with a provider is consistently among the most important factors in effective pill use (176).
Addressing Common Side Effects
Counseling pill users about possible side effects can improve OC use. Side effects cause more women to discontinue pill use than any other factor. Pill users who have realistic expectations are more likely to manage common side effects better and thus continue using the pill (38, 88, 180, 235).
For example, in Bukidnon Province, the Philippines, women who were counseled about potential OC side effects and who rated their provider as friendly were less likely to stop using the pill than women who did not receive such counseling. Based on these findings, provider training in the Philippines now emphasizes friendly interaction and explaining common side effects (191, 196).
Despite such findings, other studies show that many OC clients know little about the possibility of side effects and how to manage them. Studies in 10 sub-Saharan African countries, for example, found that only 25% to 54% of family planning users were informed about side effects during counseling. Even fewer received information on managing common side effects–from just 1% in Cote d’Ivoire to 42% in Burkina Faso, among the five countries with data (138).
Explanations that women can understand help them continue to use the pill until the side effects subside. A Nepal program puts side effects in a familiar context by comparing them to changes that occur during pregnancy: “Just as a woman’s body changes when she is pregnant, so changes can occur when she prevents pregnancy. But these changes are not dangerous” (105).
Training can improve counseling. In training, providers can learn more about both contraceptive methods and how to counsel effectively. What providers know about the pill affects how their clients feel. For example, in Colombia providers who reported having ready access to information on the pill received high ratings from clients in interpersonal communication skills and quality of care (62).
Training can help a wide range of pill providers, including clinic staff, pharmacists, social marketing agents, and community-based health workers. In Gujarat, India, for example, gynecologists, general practitioners, and pediatricians who had special training about the pill improved their counseling skills. Trained providers, when compared with others who had not received the special training, were more likely to show clients how to use the pill and to provide a pill packet at the counseling session. In turn, clients’ perception of the quality of care improved. In a study using “mystery clients”–local women who visited clinics posing as clients–satisfaction with counseling averaged 83% for the specially trained doctors compared with 56% for doctors without the training (204).
On-the-job training during working hours often can help providers apply their new skills more effectively than formal offsite training because trainees develop skills within the work environment (215). In Kenya trainers noted that providers with on-the-job training were better counselors than those who had been trained otherwise. This was because the providers encountered a variety of clients on the job, thus honing their counseling skills (68).
Performance improvement refers to a process for achieving better results from me performance of organizations and individuals. In family planning the goal is to provide high-quality, sustainable health services (188).
Performance improvement goes beyond training to address the institutional, organizational, and managerial factors that affect health care delivery. The performance improvement approach recognizes that achieving better quality of care, including better counseling, is the responsibility of the entire health care system, not just of providers and trainers themselves. Each part of a health care delivery system has a role to play in improving quality (107, 116).
In particular, assuring providers enough time to counsel their clients would improve the quality of care they can offer. Most providers have so many duties and so many clients that time for counseling is limited. In Bangladesh, for example, rising demand for the pill reduced the amount of time that field workers had to counsel each woman on proper pill use. The result was that, as more women used the pill, fewer women knew correctly when to begin their next pill pack (123). Removing administrative burdens on providers, such as excessive paperwork, can free up time for counseling.
Enabling staff to make improvements in their working environment can increase the quality of care they provide and boost job satisfaction (116). When staff members feel empowered, they often find ways to solve institutional problems rather than to keep working in an unsatisfactory setting (56).
Offering print materials to take home can help clients continue to use the pill effectively. These materials can serve as a reference if women forget pill-use instructions or have questions about starting pills, making up missed pills, switching from one pack to another, recognizing symptoms that need medical attention, and other aspects of pill use.
Package inserts and other take-home materials can supplement and reinforce information from providers (128). Take-home materials are most effective when they are concise, easy-to-read, and include specific instructions on what to do about missed pills (240). Pictures of the packet can show which pill to take first and the correct order in which to take the rest (5, 59).
Although pill manufacturers often produce package inserts for commercially marketed pills, these may be difficult to read and understand for many women (240). Locally produced information and materials can be better because they can be tailored to the clientele. Such inserts can be as simple as an information sheet stapled to the pill packet. In the Dominican Republic studies showing that women often do not take their pills on days when they do not have sex prompted PROFAMILIA, the country’s major non-governmental family planning organization, to develop an information sheet for pill users that emphasizes the need to take the pill daily even when no sexual activity takes place (87).
Reinforcing provider’s instructions through pill-pack inserts and in other ways helps women use the pill more consistently–provided that women understand these instructions. A study in Western Europe found that women who had read and understood all of the information in the inserts were least likely to miss one or more pills per packet. About 17% of such women reported missing pills. In contrast, among women who understood little or none of the information, about 30% missed one or more pills per packet (182).
Providing information on pill use in different ways and in formats that allow later review also influences how effectively women use the pill. In a study in the Netherlands some clients took home either an informational brochure or a brochure together with an audiotape, while others received only the usual counseling. Women who received the most information missed significantly fewer pills during the first several pill cycles than women receiving only the usual counseling (40).
A few drugs compromise OC effectiveness (see box). Take-home information should list these drugs specifically and remind women to use a back-up method or abstain if they are taking any of these medications. Information sheets also should mention that, because severe vomiting and/or diarrhea may diminish the pill’s effectiveness, a back-up method of contraception or abstinence may be used for 7 to 14 days in the event of these illnesses.
Following up with clients to ensure proper pill use is another important part of good counseling. Although follow-up visits usually should not be required for OC users, consultations within the first two to six months can improve continuation among women experiencing common side effects, since this is when such problems are most likely to occur (84, 180).
Clients must know that they can contact a provider at any time and ask any questions, and providers need to ensure that women always feel welcome (85, 175). Providers should welcome any OC user seeking help or advice–whether she initially received supplies from that provider or not. At a follow-up visit providers can reassure women who are experiencing side effects and offer help managing them (see box). If a woman does not want to continue OC use, the provider can help her choose another method. Providers also can assess whether the pill is still medically appropriate for continuing clients.
Women often stop using the pill without consulting their providers (3, 168, 180, 227). Indeed, being able to stop the method without seeing a provider is an advantage of OCs. Nonetheless, appropriate follow-up counseling can help potential discontinuers avoid unintended pregnancies by helping them either continue using pills with satisfaction or switch to a more suitable method.
Follow-up for providers. Like clients, providers also need continuing attention to maintain their knowledge about OCs. In Gujarat, India, for example, studies during the year following training about the pill found that trainees forgot some of the skills they had learned. In response, newsletters and home study courses were introduced to help maintain accurate knowledge (204). Similarly, in Nepal the weekly radio program for community health workers refreshes listeners’ knowledge by presenting information on different contraceptive methods, portraying effective provider-client counseling, and offering quizzes about topics presented in the broadcasts (106).
Keeping Guidelines Up to Date
Family planning programs can help OC users by following current scientific guidelines about appropriate OC use. Guidelines cover such matters as who can safely start and continue using OCs, how to use OCs effectively, and who can provide OCs under what circumstances.
The hormonal content of today’s OCs has decreased considerably from that of the first pills, and research has answered many questions about OCs and women’s health. Many earlier concerns about pill safety, which had led to various limitations on pill use, have now been satisfied (16). Some family planning programs, however, have not updated their policies, procedures, and training to reflect this new information.
Applying up-to-date medical eligibility criteria for OC use, removing unnecessary barriers that restrict access, and overcoming provider bias are particularly important to helping women use the pill.
Medical Eligibility Criteria
Who is medically eligible to use OCs? Who should not use OCs for health reasons? Recent international scientific consensus on medical eligibility criteria and family planning program procedures offers guidance. (See Population Reports, Family Planning Methods: New Guidance, Series J, No. 44, October 1996.)
Under the auspices of the World Health Organization (WHO), scientific experts met in 1994, 1995, and March 2000 to make recommendations for updating medical eligibility criteria for major family planning methods based on a review of scientific findings. These criteria help increase access to family planning methods among people who are able to use them safely, while at the same time they help health care providers better identify those who should not use a method for medical reasons. The criteria cover both initiation and continuation of methods, and they can be applied both in settings where clinical judgment is available and where it is limited (244, 245).
The WHO guidance has been widely adopted and applied. For example, the checklist for initiation of combined oral contraceptives in community-based programs (see checklist) reflects the latest recommendations of the WHO expert group. Community-based workers can use the checklist to assess whether a client can use OCs without seeing another provider, or whether the client needs to be referred to a provider who can exercise more clinical judgment. The checklist questions cover all the major medical reasons that combined OCs should not usually be used.
Removing Unnecessary Barriers
Legal, medical, service delivery, and other barriers can block access to family planning. Some barriers exist for a sound reason–to protect people from possible harm–but others have little medical or scientific basis and thus are unnecessary. Barriers to OC use include not only inappropriate eligibility restrictions but also cumbersome service delivery procedures, restrictive statutes and regulations, and provider bias (198). By updating service delivery guidelines, adopting new procedures, urging changes in outmoded rules and regulations, and encouraging performance improvement, family planning programs can remove unnecessary barriers to effective OC use.
Eligibility barriers. Some health care programs or providers require women to meet certain requirements for OCs that have no medical basis. Eligibility criteria related to age and parity, for example, have no medical basis but nevertheless are widespread (81, 200, 222). For example, in a 1992 survey in Pakistan 3 of every 10 family planning providers said that a woman had to be at least 25 years old to use the pill, while 4 of every 10 said women over 35 years could not use the pill (160). In fact, age in itself is not relevant to pill safety.
Eligibility criteria and their interpretation need to be broad enough to ensure that women who cannot use the pill safely do not use it but also specific enough that they do not exclude women who can safely use the pill (222). For example, a screening checklist that includes “headache” as a condition that rules out pill use could improperly keep women who have ordinary tension headaches from using the pill (198, 210). Only 1) women who have true migraine headaches with focal neurologic symptoms (aura) and 2) women who have true migraines without aura and are age 35 or older are the focus of concern (245).
Unnecessary eligibility barriers have hampered OCs in particular, perhaps because they were the first hormonal contraceptive method. At first, many researchers and practitioners were cautious about providing the pill, concerned that OC use might be bad for women’s health or worsen existing medical conditions. Eligibility criteria established many years ago, when hormone levels in the pill were much higher and less was known about effects of the pill, have persisted today in many places, even though subsequent research and experience have proved these limitations to be unnecessary (16). For example, in the US many providers did not prescribe OCs to any woman who is diabetic (198). Research, however, has found no adverse clinical effects among diabetic OC users who have no circulatory system complications (25, 66, 154).
Process barriers. Some service delivery practices make it burdensome for clients to obtain OCs or other contraceptives yet lack scientific justification (198, 199, 209). For OCs, process barriers include unnecessary, inappropriate, or unrelated screening tests or procedures, frequent follow-up requirements, improper management of side effects, failure to give clients enough supplies, and requirements for periods of “rest” from pill use (199).
For example, required pelvic exams and laboratory tests for women who choose OCs are a burden to all women seeking OCs and a particular barrier to women who have never before had a pelvic exam or who are afraid of needles (222). In Jamaica a 1993 survey of over 350 private practitioners found that one-quarter performed blood and urine tests on women seeking the pill, even though Jamaican service delivery guidelines make no mention of either test as a prerequisite for pill use (80). In Senegal providers required Pap smears and urine, blood, and sexually transmitted infection tests–all medically unnecessary to safe pill use–before giving clients the pill. In fact, they often did not allow clients to use the pill unless they were in apparently perfect health (81). In Ghana a 1993 Situation Analysis found that 55% of providers required blood hemoglobin tests for prospective OC users, even though such tests are not medically necessary for safe pill use (161).
When these unnecessary tests are required, facilities ill-equipped to do such tests cannot provide pills, thus limiting women’s access to OCs. While some tests or procedures, such as a pelvic exam, are good preventive health practices that benefit women’s overall reproductive health, they nonetheless are not relevant to safe OC use (70, 224). No condition that a pelvic exam might detect rules out OC use (245).
Menstrual requirement. Probably the most common process barrier is to deny OCs to new clients unless they are menstruating when they see the provider (2, 60, 209). In Jamaica nearly one-half of private practitioners interviewed would send women home without pills if they were not menstruating. In another Jamaican survey 92% of providers and clinic supervisors said they required menstruation or a negative pregnancy test before they would give women any contraception. In 12 clinics surveyed in Kenya, every provider said that clients are often sent home to await menses. At the same time, over half of the clients visiting 19 Kenyan family planning sites were not menstruating at the time of their clinic visit (209).
If women are not actually sent away because they are not menstruating, they may be forced to choose a non-hormonal method instead of the pill. In Cameroon a study of 10 clinics found that only 33% of clients who were not menstruating were given a hormonal method, while 82% of menstruating women left with a hormonal method. Of 21 service providers, only 2 said that they did not require their clients to be menstruating before they would provide OCs (209).
The menstrual requirement is meant to ensure that a woman is not pregnant when she starts OCs, for fear that hormones may harm the fetus. This is also why some programs even require a negative pregnancy test before giving OCs. There is no evidence, however, that combined or progestin-only contraceptives harm a fetus (57, 67, 236). WHO medical eligibility criteria were recently changed to make clear that current pregnancy is not a condition relevant to decisions about providing hormonal contraceptives (245).
Women who want to start using OCs do not have to do so when they are menstruating: Women can begin using the pill at any time during their menstrual cycle if it is reasonably certain that they are not pregnant (84, 85, 220) (see box). By asking a series of questions, a provider can be reasonably sure that a woman is not pregnant even though she is not menstruating (208, 221). If a woman’s answers to these questions cannot affirm that she is not pregnant, a provider can still give her OCs with instructions to start the first packet when menstruation begins and can also provide condoms or spermicides to use until then.
Legal and regulatory barriers. In some countries only doctors can legally provide OCs, a requirement that can seriously limit access to the pill, particularly where doctors are few. Such restrictions have no sound medical basis. Not only physicians but also many other personnel, including midwives, nurses, community-based health workers, traditional birth attendants, pharmacists, social marketing vendors, and pharmacy clerks, are safely providing OCs around the world. OCs are made available through door-to-door delivery to people’s homes, at community centers, and in shops, markets, and grocery stores (183, 199, 222) (see p. 20).
Unnecessary prescription requirements. In some countries, notably the United Kingdom and the US, OCs are available to women only by prescription. Given the proven safety of low-dose OCs, the widespread demand for the pill, and safe use of OCs among women obtaining them without a prescription throughout the world, some experts argue that OCs should become available without prescription everywhere (30, 69, 167, 224).
Making OCs available only by prescription requires women to overcome a series of hurdles to start the pill and to keep using it. First, they must see a physician or other specified health care provider, often endure a pelvic exam, and obtain a prescription for the pill. Then they must go to a pharmacy to have the prescription filled, often for only one pack of pills at a time. Women must continue to return to a pharmacy every month to get another pill pack and return to the doctor every year to have the prescription renewed.
Researchers debate the impact that availability of OCs without prescription might have on access, safety, effectiveness, cost, and preventive reproductive health care (28, 39, 69, 70, 79, 92, 167, 187, 189, 224, 249). Eliminating a visit to the doctor–and consequently, the pelvic exam–could increase access to the pill for women who are intimidated by a pelvic exam, cannot afford a provider visit, or are embarrassed to be seen entering a family planning clinic (69, 213, 224). Not seeing a provider for a prescription, however, could also mean that fewer women receive preventive health care screenings such as yearly Pap smears, breast exams, and screening for reproductive tract infections (79).
Some are concerned that, without a required visit to a doctor to obtain OCs, women will not heed warnings about health conditions that rule out pill use, such as migraines with aura, high blood pressure, and other circulatory system disorders, and, for women age 35 or older, smoking. They argue that lack of provider intervention would compromise pill users’ health, since women who should not use the pill may begin using it if a provider is not there to disallow OC use (79, 213, 249). Studies have shown, however, that giving women accurate information about health conditions and risks helps them correctly assess their own health risks and decide for themselves which methods are most appropriate. In fact, often they can do so as well or better than providers (29, 167, 250). Thus, others argue, women are fully capable of making the right decisions about their health risks.
What would offering the pill without a prescription mean for the pill’s effectiveness? Some argue that a doctor’s or nurse’s instructions help women use the pill more effectively (79, 213, 249). Others contend that, given the current gap in pregnancy rates between perfect use and typical use of the pill, clients apparently get too little information from providers as it is. Thus, they reason, using other ways to inform women about how to use the pill may be more effective than continuing current practices (69, 167, 224).
In June 2000 the US Food and Drug Administration discussed with scientists, professional groups, and consumers the possibility of changing oral contraceptives from prescription status to being available without a prescription (30, 230).
Some providers let their personal views deny clients a full choice of methods (199). Commonly, they impose their own social values on clients. For example, almost one-third of providers in Burkina Faso and close to 10% in Kenya said that they required spousal consent for OC use (137). Many providers and even programs deny family planning to young women, particularly if they are not married (161).
Providers may incorrectly believe that some groups of women cannot use the pill effectively. For example, in Vietnam providers often do not recommend OCs because they think that clients could not remember to take a pill every day (78). Also, in South Africa women with less education predominantly use injectables, while women with more education mostly use the pill. This difference occurs because providers incorrectly assume that only well-educated women can use the pill consistently and correctly (41, 174). Others may judge clients on the basis of socioeconomic status and treat women of higher status better than those of lower status. In Gujarat, India, for example, a study of OC providers found that they devoted more time to counseling clients of higher social standing (204). Many providers are rude to poor clients, as a study in Bangladesh found (190).
Some providers make judgments based on their perception of a specific woman’s situation. For example, if providers think that a woman does not want her husband to know about her contraceptive use, they may not offer the pill. They assume that hiding the pill packet would make consistent use too difficult for her (15).
Providers’ and programs’ bias in favor of OCs may actually contribute to ineffective use and early discontinuation among some users. No method is ideal for all users at all times. When providers have preconceived notions that certain clients “should” use OCs, some of their clients will end up with a method that does not suit them well. These clients are not likely to use the pill correctly or for long. Similarly, programs that offer OCs and just one or two other methods leave many women with little choice but to use OCs, whether or not the method suits them.
Making it easy to obtain OCs helps women use them effectively. Providing good access includes ensuring regular supplies, making pills affordable, and offering them conveniently. If access is difficult, some women discontinue using the pill, while others try to stretch their supply by not taking a pill every day. Still others may switch to less effective methods that are easier to obtain or do not require frequent resupply.
The following can help programs make the pill more affordable, convenient, and accessible:
* Better access to family planning clinics,
* Community-based distribution,
* Social marketing,
* Encouragement for the commercial sector,
* Links between pill provision and other health services.
Whatever the program, good logistics management is crucial to making OCs available continuously and in ample supply.
Better Access to Clinics
As with other contraceptive methods, women who have easy access to the pill are more likely to use it. Several studies have demonstrated that distance from a family planning clinic and the time required to reach it are important to whether women use a family planning method (169, 226). For example, in Thailand a study found that the closer clients lived to a family planning delivery site, the more likely they were to use contraception. Even living a few more minutes away made a considerable difference. For instance, among women who lived less than three minutes from a clinic, 47% were using the pill compared with just 24% among women living six or more minutes away (49). Similarly, in Egypt, pill use fell markedly as travel time to the source of supply increased (108).
Having a convenient place to obtain more pills also helps ensure continued use. For example, in Ghana a study of women obtaining pills from a clinic found that nearly half of the pill users who did not return to the clinic for more pills nevertheless kept using the pill. They preferred to buy pills from a more convenient location–often chemists’ shops near their homes. Women with a convenient source of supply were over three times as likely to continue OCs over a year-long period and twice as likely to continue using them over a two-year period as women without a convenient source of supply (227).
This study suggests that family planning clinics should not assume that clients who do not return for resupply have stopped using the pill. Particularly where pills are accessible in many types of places, many women obtain them from the most convenient source. Thus, even for women who obtain pills initially from clinics, making pills accessible in all kinds of public and commercial locations, including those unrelated to other health care, can help women continue using the pill. Providers can inform clients not only about clinic-based services but also about other sources of pills (151).
Giving more pill packets. Giving a woman more than one pill packet at a time reduces the chances that she will run out of pills. In addition, decreasing the number of times a client has to return to a clinic reduces clinic congestion and waiting time. Giving a woman 13 packets–a full year’s supply–is ideal if she has no health condition, such as nonvascular diabetes, that needs to be monitored (84, 85). After the first year of pill use, clients can have another year’s supply or even an 18-month supply, if expiration dates on the pill packs permit (84, 95).
If not enough supplies are on hand to give pill users a full year’s supply, women should receive at least three or four packets. Plans for follow-up should leave enough time to obtain more pills well before her supply runs out (84, 111, 180, 235). In the early years of the pill, monthly follow-up was sometimes recommended with higher-dose pills to monitor women closely for any serious side effects. Today’s lower-dose pills, however, are safer than ever, and no routine follow-up is needed except for resupply (220). Still, providers often limit how many packets they give out because they think, incorrectly, that they need to monitor the health of pill users (228).
Community-based distribution (CBD) provides some women’s only access to OCs. Through CBD, specially trained workers bring OCs and other family planning supplies to communities and homes.
In some countries CBD is an important component of the national family planning program. In Zimbabwe, for example, where rates of OC use are among the highest in the world, the CBD program serves nearly one family planning client in every four (14). In Bangladesh a study projected that in 1993 family planning use in certain areas would have been only 25%, rather than 40%, if CBD had not been a major component of the country’s family planning program (155).
CBD is particularly important where there are no health centers or commercial sources of contraception. In 18 villages in Mall where family planning services were not available, for example, only 1% of women used family planning. Six months after a CBD program began in these villages to offer OCs, spermicides, and condoms, contraceptive prevalence had risen to 31% in villages where all three methods were offered and to 21% where spermicides and condoms but not OCs were offered (45).
Regular visits by CBD agents providing supplies and counseling improve OC continuation. In Bangladesh women who had been visited at home by family welfare assistants within the previous 90 days were two-thirds as likely to have discontinued use than women who had not been visited in the last 90 days. The effect of home visits on continuation was strong–and consistent for women of all social and economic backgrounds–even though social marketing outlets and clinics were accessible in the study area (91).
Screening clients. Screening clients to identify which women can safely use hormonal methods is an important part of CBD programs. By using checklists, CBD agents can accurately identify women who should not use a method without impeding access for women wanting to start OCs (210) (see “Checklist for Clients Who Want to Initiate Combined Oral Contraceptives (COCs) in Community-Based Services”). CBD agents also can use a checklist to assure that continuing clients have not developed a medical condition that makes pill use inappropriate.
In the Dominican Republic PROFAMILIA’s CBD agents use a card to screen potential OC users. By checking off the appropriate color-coded boxes as clients respond to eight yes-or-no questions, the agent decides to:
(1) Provide the pill;
(2) Provide the pill but ask the client to see a physician within three months for follow-up; or
(3) Ask the client to see a physician first (87).
Anyone with specific training, supervision, and performance evaluation can provide OCs safely and effectively (246). Programs must ensure that screening guidelines are up to date with current scientific knowledge and practices (see p. 17). They must also ensure that CBD workers have had adequate training and practice in properly using the screening checklists (210).
Community outreach and participation. Community outreach and participation efforts help provide a supportive social setting that makes it easier for women to use the pill correctly and continuously. One example of such participation is monthly meetings in a community member’s home or a community center. At such meetings health care providers and members of the community gather together, creating an opportunity for women to talk about family planning, support one another’s family planning use, and receive OCs and other contraceptives. This approach has been successful in Bangladesh, where social support was found to be the strongest motivating factor in women’s decisions to use and continue using contraception (113, 156). Much of the success of the Indonesian family planning program has also been attributed to community outreach and involvement (217).
Social marketing improves access to methods such as OCs by making them widely available, well known, and affordable. The social marketing approach is to offer contraceptives for sale in the commercial sector at subsidized prices, while promoting them in the mass media and where they are sold. Social marketing offers the pill in places where users are already likely to be shopping, including markets, kiosks, and grocery stores, thus often eliminating the need for a special trip to obtain pills.
Social marketing is widespread. In 1998, 40 social marketing programs sold nearly 66 million pill packets to women in 34 countries. These numbers are substantially higher than in 1991, when 18 social marketing programs sold about 22 million pill packets in 17 countries (82, 83).
Some social marketing programs now operate without subsidy, sustaining themselves wholly from the sales of contraceptives. In Colombia PROFAMILIA’s social marketing is completely self-sustained, as are programs in Jamaica and Malaysia. Indonesia’s Blue Circle social marketing is largely self-sustaining (83).
Some clients are willing and able to pay full price for family planning services. Growing numbers of users prefer to pay for pills from the private sector, where they can obtain the quality, convenience, and continuity of service that private providers often offer. The commercial sector includes doctors, pharmacies, clinics, and hospitals that are generally financially independent of government or donor agency subsidies (61).
Promoting expansion of the commercial sector improves access to OCs because it offers users more places to obtain pills. Also, when family planning users switch from the public sector to the commercial sector, public funds can go further to improve access for those who cannot afford full price. Government action can stimulate commercial sector growth. For example, placing the pill on a country’s list of essential drugs can reduce import barriers, making OCs less expensive. Such changes can make private sector investment in family planning goods and services more feasible economically and more attractive (61).
Governments can do much to expand the role of the commercial sector in providing OCs and other contraceptives. Indonesia’s government launched the Blue Circle campaign in 1987 both to stimulate demand for private family planning services and to expand the number of private providers. As a result the percentage of family planning users obtaining supplies from the private sector rose from 12% initially to 57% a decade later (23, 24, 99).
Links Between Pill Provision and Other Health Services
Linking family planning services with other health services can make the pill more accessible, especially to women who have not been using any contraceptive method. Clients who may not have sought out a family planning facility can obtain OCs or other methods while receiving other health care. There are several kinds of links:
Postpartum family planning. Maternity care programs can offer the pill and other family planning options. In Honduras, when progestin-only pills and condoms were offered to women after delivery, the percentage choosing family planning after delivery rose from 9% to 30%. Some 61% of women who returned for a 40-day postpartum check-up chose a contraceptive method during the visit (21, 196).
Women not breastfeeding their infants can start combined OCs 21 days after delivery, or they can start progestin-only OCs immediately after delivery. Breastfeeding women can start progestin-only pills at six weeks postpartum, or they can start combined pills either at six months after delivery or when they stop breastfeeding, whichever comes first (85, 245). In either case, women can be given the pills at any convenient time, such as after delivery or at a postpartum check-up, with instructions on when to start using them. Thus these women will not have to make a special trip for supplies when they are ready to start OCs.
Postabortion family planning. Fewer than one-third of women in Latin America, Africa, and Asia receiving care for postabortion complications have ever used a modern contraceptive (185). Women experiencing spontaneous or induced abortion return to fertility almost immediately. Therefore facilities treating women for postabortion complications should also offer family planning counseling and services.
Offering family planning as part of postabortion care can make a dramatic difference in contraceptive use. Many women being treated for postabortion complications want family planning. In Egypt, for example, 62% of postabortion patients decided to use a family planning method after counseling by a specially trained provider. Before family planning counseling was made a part of postabortion care, only 37% of patients decided to use family planning (98). Similarly, in Kenya before family planning counseling became part of postabortion care, only 7% of postabortion patients received contraceptive counseling, and only 3% obtained contraception. Afterwards, 68% of clients were counseled, and 48% received their chosen method (205).
Child health clinics. Offering family planning along with immunization and other child health care services can be simple and successful. For example, immunization clinic workers in Togo selected 1,000 women randomly while their children were being immunized and said just three sentences to each about the availability of family planning methods at the clinic and the health benefits of child spacing. Six months later the average number of new contraceptors per month at the clinic had increased by 54% (97, 196).
Good Logistics Management
An effective contraceptive distribution system is crucial to provide women with pills reliably and regularly (54). Pills are not fully accessible if they are in short supply or entirely out of stock. Lack of attention to logistics management can undercut all other efforts to improve supplies and services.
For example, in Uganda a program trained nurses to provide OCs, condoms, and Depo-Provera injectables in several communities. Within three months the number of new clients increased 84%. The contraceptive logistics system, however, did not keep up with the increase in family planning users, and supplies ran short in four of nine districts (114). If contraceptive supply remains irregular for long, clients lose confidence in a service provider. Clients are less likely to return for services when they presume that their chosen method will not be available (54, 131).
Family planning programs can use a variety of techniques to maintain a continuous supply of OCs. These include warehouse and distribution management, commodity forecasting, distribution resource planning, and logistics information technology. The essential element is to calculate the optimal number of supplies to order and thus reduce waste, operate more efficiently, and ensure access (54, 131). Stockouts of progestin-only pills at service delivery points in Malawi fell from nearly 80% in 1998 to 10% in 1999 after a field-level distribution and logistics information system was set up (54).
Toward More Effective Use
Over 100 million women throughout the world rely on oral contraceptives to meet their family planning needs. With adequate financial and policy support, family planning programs and providers can help women use the pill effectively by:
* Increasing knowledge about the pill through mass-media messages and other communication channels. As women learn more, they are better able to make informed decisions about their reproductive health, to choose a contraceptive method that suits their needs, and to use this method effectively and with satisfaction.
* Improving the ability of providers to inform and counsel women about the pill. When providers can communicate clearly how to use the pill–in particular, how to manage side effects and how to make up missed pills–clients use the pill better and longer.
* Making OCs and other methods easily available. The fewer barriers that women face to obtain the pill, both initially and for resupply, the better they can rely on the pill to prevent pregnancy.
Forty years after the introduction of the pill, family planning programs and providers have the knowledge, ability, and experience to help women use OCs effectively in order to achieve their family planning goals, improve their reproductive health, and reduce the number of unintended pregnancies. Helping women use the pill contributes to safety, effectiveness, and users’ satisfaction, now and in the future.
Missed Pills and Pregnancy: When Are Women Most at Risk?
Recent studies have come closer to understanding when the risk of pregnancy is greatest for women who miss pills: Extending the hormone-free interval most increases a woman’s risk of breakthrough ovulation (122, 140, 233). This can happen if a woman misses pills in the third week immediately before the seven-day hormone-free period or if she starts the next pack late. Women’s normal pre-ovulatory hormonal functions resume during the seven days of not taking hormonal pills. Follicles begin to develop on the ovary–the precursor to ovulation.
Researchers have removed different numbers of pills at different places in the pill pack in an effort to identify how many days without hormonal pills it takes for women to ovulate. Some packets had two, three, or four hormonal pills removed from the third week. Others had hormonal pills removed at the start of the packet: days 1-4, 3-6, or 6-9.
These studies involved various low-dose formulations, both multiphasic and monophasic, including those with one of the lowest available doses of ethinyl estradiol, 20 [micro]g. While results varied–from no ovulation to ovulation in 10% of women in one study–in every study women developed ovarian follicles (48, 112, 121, 122, 127, 140, 203,219).
A review of the findings from these studies, coupled with observations about pill-taking and pill failure, suggest several conclusions:
* Some women are biologically more likely to become pregnant than others. These women quickly achieve normal hormonal levels during the hormone-free interval, making missing only a very few pills on either side of the hormone-free interval extremely risky (118). In fact, variation in follicular development is so great among women that some researchers feel that individual body chemistry can be a greater risk factor for pregnancy than missing a specific number of pills (112, 118, 219).
* While women do resume normal pre-ovulatory hormonal function during the seven-day hormone-free interval, this does not compromise the effectiveness of the pill. Hormonal levels have not been shown to rise to those needed for ovulation, cervical mucus remains thickened, and the lining of the uterus remains thin throughout these seven hormone-free days (112, 118, 140, 203).
* For most women, taking seven hormonal pills in a row is enough to provide maximum contraceptive effectiveness, even immediately after the seven-day hormone-free period (118). Studies looking at follicular development among women missing pills found that the follicles regressed in the majority of women after seven days of taking hormonal pills (112, 118, 140, 203). Some women, however, may need more than seven pills to make the follicles on the ovary regress and thus establish full contraceptive effectiveness (118).
The evidence from these missed-pill studies has been used to revise guidelines for making up missed pills. Because women are at greatest risk of pregnancy when they go more than seven consecutive days without taking hormonal pills, the “seven-day” guideline focuses on avoiding an extended hormone-free interval (see box).
Shortening the Hormone-Free Interval
Shortening the hormone-free interval–that is, reducing the number of days a woman does not take hormonal pills to less than seven–may help reduce the risk of breakthrough ovulation if women miss pills immediately before or after the hormone-free interval (216, 252). Such a pill regimen, Minesse[R], was approved in Europe in March 2000 and contains 24 hormonal pills and 4 nonhormonal pills (252). This is an ultra-low-dose pill, containing only 15 [micro]g of ethinyl estradiol and 60 [micro]g of gestodene.
When compared with a 21-day hormonal pill formulation with 20 [micro]g of ethinyl estradiol and 150 [micro]g of desogestrel, the 24-day hormonal pill pack was just as effective in preventing pregnancy (252). Women using the 24-day hormonal pack had shorter and lighter withdrawal bleeds and more breakthrough bleeding than women using the 21-day hormonal packets. Fewer women discontinued due to breast tenderness or nausea with the 24-day formulation (252).
Using the “Seven-Day” Guideline to Make Up Missed Pills
The simple basic instruction for effective pill use is, of course: Take one pill each day. Beyond that, thinking in terms of seven days can help a woman avoid pill-taking errors and correct for mistakes: For full protection, do not go more than seven days without taking hormonal pills. If you miss two or more pills, keep taking hormonal pills for at least seven days straight to stay protected. A woman can apply this guidance to avoid the riskiest pill-taking error–extending the gap between cycles–and to make up for missed pills.
The “seven-day” guideline reflects research on how women’s hormonal cycles respond to the pill. This guideline is based on observations that usually up to seven straight days of taking pills are needed to suppress a woman’s hormonal cycle at the beginning of a pill pack (112, 118, 140, 203). It also recognizes that women are not at risk of pregnancy for the seven days they are not taking hormonal pills at the end of the pack even though their bodies are producing the hormones that start the process of ovulation (112, 118, 140, 219). This research indicates that it is riskiest to miss the pills that increase the number of days women are not taking hormonal pills–those at the beginning and end of a pill pack (see box).
Over the years a variety of rules were proposed to help women make up missed pills, but no consensus developed. The “seven-day” guideline was developed by John Guillebaud and the Family Planning Association of the United Kingdom.
Starting a New Pill Pack Late
The seven-day guidance highlights the importance of starting the next pill pack on time–no more than seven days after the last hormonal pill from the previous pack. If a woman does start a pack late, a back-up method or abstinence will protect her until she has taken pills for seven days (see diagram, A).
[Diagram A ILLUSTRATION OMITTED]
Missing One Pill
If a woman misses only one pill, she should take one as soon as she remembers having missed one. This may mean taking two pills on the same day. She can continue taking the remaining pills as usual, one per day.
Missing Two or More Pills
First or second week. If a woman misses two or more consecutive pills in the first or second week of the pack. she should follow the seven-day guidance taking a pill as soon as she remembers and continuing to take the rest of her pills as usual, one per day. By the time she reaches the last of the hormonal pills in that pack, she will have taken pills for at least seven days straight (see diagram, B).
[Diagram B ILLUSTRATION OMITTED]
Third week. The third week of the pill pack is the most important time to follow the seven-day guidance because adding several days of missed pills to the usual seven-day hormone-free interval between packs may result in breakthrough ovulation in some women.
If a woman misses two or more pills in a row during the third week of the pill pack, she should be sure to take at least seven pills straight. A 21-day user can do this by taking one pill as soon as she remembers and then finishing the hormonal pills in the current pack. She then should start a new pack the very next day, without the usual seven-day wait (see diagram C).
[Diagram C ILLUSTRATION OMITTED]
A woman using 28-day pill packs should skip the pills in the fourth week because these pills contain no hormones and do not count toward seven straight days of pill-taking. She should then start a new pack the next day after taking the last hormonal pill (see diagram, C).
Fourth week (28-day users). A woman missing pills in the fourth week can throw the missed pills away. She should continue taking the remaining pills on schedule, being sure not to go more than seven days between taking hormonal pills (see diagram, D).
[Diagram D ILLUSTRATION OMITTED]
Providers Play a Key Role
Providers play a key role in women’s successful use of the seven-day guidelines. Instructions on making up missed pills are usually the most difficult instructions for providers and pill users to remember. Instructions must be detailed enough to prevent unintended pregnancy but simple enough to remember and follow.
Some providers may feel that the seven-day guideline is too complex to remember and follow, since women take different actions depending on when two or more pills are missed. When women understand the principle of the seven-day guideline, however, they are able to apply it correctly when they miss pills. The seven-day guideline is now the standard in the United Kingdom. where providers report that women can easily remember–and apply–this guidance (71, 74, 252).
In order for pill users to understand the principle behind the seven-day guidance, providers must tell women how pills work. and that for seven days every month they are not taking hormonal pills. This is especially important for 28-day users to remember. Good counseling can help. Telling women that the pill puts their ovaries to sleep and that missing pills can wake their ovaries up is a good way to explain it in understandable terms.
Most Pill Users’ Pregnancies Occur When They Quit but Do Not Switch
Based on an estimate for the US by Michael Rosenberg and colleagues (181), an estimated 10 million of the world’s 106 million OC users will become pregnant in a one-year period (see Figure 2). Pregnancy during pill use, however–whether due to incorrect or inconsistent use or to technical failure–accounts for only about one such pregnancy in every five.
[Figure 2 ILLUSTRATION OMITTED]
The other 80% of pregnancies in 12 months after starting OC use will occur among the one-third of women who discontinue pill use. In particular, 68% of unintended pregnancies will occur among the 12% who discontinue pill use and do not switch to another method. (Another 11% of pill users will not need another method once they stop using the pill; they are no longer fecund, want to become pregnant, are not having intercourse, or have already become pregnant. About 5% will adopt a less effective family planning method after discontinuing the pill, and about 7% will switch to a more effective method.)
Among women who discontinue OCs and do not adopt another method within 12 months despite continuing need, over half–nearly 7 million women–will become pregnant. This estimate is based on a study of Ghanaian pill users, which found that 53% of pill discontinuers became pregnant within several months (227).
Thus most pill users who become pregnant actually become pregnant when they stop OCs without switching to another method. Family planning programs should focus on helping women continue their methods or switch to new methods without a gap in contraceptive protection. In particular, providers can advise OCs users about common side effects and their management and emphasize that clients are welcome back to seek help or another method at any time.
Men Can Help
Women can use the pill more effectively with their partners’ involvement and support. Studies demonstrate that, when partners participate in the selection and use of OCs, women use OCs longer, manage side effects better, and even use pills more effectively. For example, in a study of 10 clinics in Guatemala, Hong Kong, Jordan, Kenya, Nepal, and Trinidad and Tobago, women used the pill longer when it was their first choice and their partners agreed that they should practice family planning (96).
Similarly, in rural Bangladesh women whose husbands participated in selecting OCs used them longer than women whose husbands were not involved in selecting a family planning method. These women also reported lower rates of discontinuation due to common side effects. Researchers report that husbands helped by urging their wives to obtain more information or counseling from a provider about how to manage side effects. Discussing her side effects with her partner can relieve anxiety. Such discussion also promotes switching to a different method when appropriate (170).
When men help in selecting a contraceptive method, they are more likely to be involved in its correct use. A Chinese study looked at the effect of partner involvement on contraceptive use-effectiveness. The pregnancy rate for users of temporary methods was lower among women who attended contraceptive counseling with their husbands than among women who obtained a method on their own (232).
Of course, men also can influence their spouses to stop using family planning. Some 37% of women in Bangladesh who had stopped using the pill in less than three months reported that their husbands influenced them to stop (3).
Family planning programs can reach men in a variety of ways, especially at places where men gather–for example, at sporting events and community meetings–as well as through mass-media messages (46). Pill use messages in the mass media can speak directly to men and their participation in better reproductive health, including telling them how they can help their partners use the pill effectively. (See Population Reports, New Perspectives on Men’s Participation, Series J, No. 46, October 1998.)
Key Counseling Messages About the Pill
Pill users need to understand a lot about the pill. Some of the information helps a client choose among methods and need not be remembered to take the pill effectively. Other messages need to be remembered. This list highlights some key take-home messages.
* The pill works if you take it correctly. It is up to you to make pill use as effective as it can be. You must remember to take a pill every day as long as there are pills in the pill packet.
* Take action if pills are missed. It is important to make up missed pills, abstain from intercourse, or use a back-up method of contraception if you do not want to get pregnant. (See box.)
* Vomiting, diarrhea, and certain medications can make the pill less effective. (See box.)
* Be sure to start a new pill packet on time. If you start a new packet late, use a back-up method or abstain from intercourse until you have taken pills for seven days straight.
* The pill does not prevent sexually transmitted infections (STIs).
If you are at risk for STIs, use condoms or abstain from intercourse. (You can use condoms and pills at the same time for extra protection against pregnancy.)
* Most common side effects do not mean something is wrong. Continue taking a pill each day. Skipping pills can make side effects worse. It may take a few months to adjust to the pills and for side effects to diminish or go away entirely.
* You should immediately see a health care provider if you experience:
– Constant, severe pain in chest, legs, or abdomen;
– Severe, recurring head pain, often on one side or pulsating, that can cause nausea and is often made worse by light and noise or moving about;
– Brief loss of vision, or seeing flashing lights or zigzag lines in front of the eyes (with or without bad headache); or
– Yellowing of eyes or skin.
Source: Adapted from Guillebaud, 2000 (75)
Managing Common Side Effects of Combined OCs
Explaining side effects is an important part of advising new pill users, since side effects are the leading reason that women discontinue pill use. Women considering the pill or already using it should be aware of the possibility of such common side effects as nausea, breakthrough bleeding, spotting, amenorrhea, changes in menstrual flow, mild headaches, slight weight gain, and breast tenderness or enlargement (85, 235). All pill users should be advised that these common side effects are not signs of danger or serious illness.
Common side effects of pill use typically subside within the first three to six months of use (37, 163, 179). Breakthrough bleeding decreases dramatically over the first four months of pill use (84, 136).
How can providers help women with side effects? First, they can urge all OC users to tell them if side effects occur and assure them that usually something can be done to manage side effects. Often, simply letting women know that they can return to consult the provider at any time helps women use a method longer, despite side effects (93, 126). When a pill user returns for help with side effects, the strategies below can help to reduce them.
Breakthrough bleeding and spotting. Some women experience breakthrough bleeding or spotting when they miss pills or take them at different times during the day. For these women, taking the pill every day and at the same time can help reduce breakthrough bleeding and spotting
Other women, however, have these side effects even when they take their pills consistently. For women whose breakthrough bleeding occurs early in the pill cycle, changing to a pill with more estrogen, if available, can help reduce bleeding (84, 136). Sometimes switching to another low-dose pill formulation can help.
Women with vomiting and diarrhea sometimes experience breakthrough bleeding and spotting (84, 85). Interactions with specific drugs can cause breakthrough bleeding, too (72). Vomiting, diarrhea, and drug interactions affect how the body absorbs the hormones in the pill. Breakthrough bleeding may indicate that the pill is not being fully absorbed, and thus the pill’s contraceptive effect may be compromised. These women should continue taking a pill every day, and for added protection they can use a back-up method or avoid intercourse during the period of vomiting, diarrhea, or drug use and for 7 to 14 days afterward (74).
Nausea. Feeling nauseous usually passes after the first few months of pill use, usually occurs on the first day or so of the pill pack, and is more common among women who are underweight (73). Taking the pill at night or with food can help reduce nausea, as can consistent pill-taking (84, 85).
Weight gain. In most cases, weight change among women using OCs is minimal and not related to pill use: As many women lose weight while taking the pill as gain weight (84). Some women may gain substantially, however.
While some women see weight gain as a benefit, others may not be pleased. Reducing the level of estrogen may help keep women from gaining weight (84).
Amenorrhea. A small number of pill users stop menstruating when using the pill. More often, a woman’s bleeding may be so slight or so brief that she may think she is not bleeding at all. Such apparent or actual amenorrhea can upset women who believe that regular menstruation is necessary to remain healthy or have certain folk beliefs about menstruation (90, 195). Others may be worried that lack of menstruation indicates pregnancy.
Asking pill users several questions can help identify what steps can be taken. Is the woman having any bleeding at all? Perhaps she has just a small stain on her underclothes that she has not recognized as bleeding. If this is the case, these women can continue taking their pills every day, with reassurance that not menstruating is not harmful to their health.
Although amenorrhea is not usually a sign that a pill user is pregnant, providers can verify whether or not this is case by asking a woman a few questions. For example, in the last month has she taken a pill every day? If so, it is not likely that she is pregnant. She should continue taking her pills every day as usual. Also, some women using 21-day packs may have no bleeding if they start another pill packet immediately rather than waiting seven days between packs. Women who have done this also are not likely to be pregnant.
For a woman who has missed two or more hormonal pills in a row, a series of questions can assess whether or not she may be pregnant (see checklist). A woman must be told if a provider suspects that she may be pregnant. This woman should stop using OCs, and she can use spermicide and condoms until her menstrual period starts or it becomes otherwise clear whether or not she is pregnant. Women who are not pregnant should feel free to start using OCs again if they wish.
A few women experience amenorrhea after they stop using the pill. Sometimes it takes women a few months for their periods to return after using OCs. No medical management is needed. Women with irregular menstrual periods before using the pill may have irregular periods again once they stop using the pill (85). Assuring such women that the pill has not affected their fertility can reduce any anxiety about amenorrhea.
New WHO Medical Eligibility Guidance
Updated guidance on medical eligibility for contraceptive use becomes available October 2000 from the World Health Organization. Based on a March 2000 expert meeting, the new guidance covers 10 family planning methods and over 50 medical conditions.
For copies contact: Dr. Monir Islam Reproductive Health and Research World Health Organization 1211 Geneva 27 Switzerland
When Can a Woman Start the Pill?
A woman can start the pill at any time that it is reasonably certain that she is not pregnant. She does not have to be menstruating when she starts the pill.
A woman who starts the pill more than seven days since menstrual bleeding began should use a back-up method such as condoms or spermicide or else avoid intercourse for the first seven days of taking the pill. Her usual menstrual pattern may change, but she should continue taking all the pills in the pack, regardless of when she next menstruates.
To make reasonably certain a client is not pregnant, a provider can ask a series of questions (see checklist). A pregnancy test is not necessary. There is no need to ask a woman to return when she is menstruating, for the pill or any other method.
If pregnancy cannot be ruled out–in other words, if the woman cannot answer yes to any of these questions–she can take pills home with her and start them as soon as her menstrual period begins or any time within the first seven days after menstruation starts.
When is the best day to start? The first day of menstrual bleeding may be easiest to remember, and starting on the first day requires no counting of days. Recent research, however, suggests that starting later reduces breakthrough bleeding and spotting in the first month. This could be an advantage because breakthrough bleeding is a common reason that women quit OC use in the first month (247, 248).
Two studies compared starting on the first day of menstrual bleeding with starting on the fifth day. In the first study 26% of the 50 women starting their pills on the first day of menstruation had breakthrough bleeding compared with 8% of the 50 women starting on the fifth day (248). In a second study 24% of 100 women starting on day 1 and 10% of I00 women starting OCs on day 5 experienced breakthrough bleeding in the first month (247). Because fewer of these women experienced breakthrough bleeding, fewer of the day 5 starters discontinued use during the first pill cycle (247, 248).
Some instructions for pill use in some developed countries have told women to start on a Sunday. This guidance has become somewhat less common because many pharmacies in these countries are closed on Sunday, making it difficult for women to obtain pills.
Checklist to Rule Out Pregnancy for Non. Menstruating Family Planning Clients
NO Please ask the client these questions, and YES
check the correct box: 1. Have you given birth in the last four weeks?  2. Are you less than six months postpartum 
and fully breastfeeding and free from menstrual
bleeding since you had your child? 3. Did your last menstrual period start within 
the past seven days? 4. Have you had a miscarriage or abortion in 
the past seven days? 5. Have you abstained from sexual intercourse 
since your last menses? 6. Have you been using a reliable contraceptive 
method consistently and correctly?
If the client answered NO to all of the questions, pregnancy cannot be ruled out. Client should use a barrier method or abstain until menses and then start preferred method.
If the client answered YES to any one of the questions and is free of signs or symptoms of pregnancy, provide her with the desired method.
Source: Adapted from Family Health International (52), based on Technical Guidance Working Group, 1997 (221).
Checklist for Clients Who Want to Initiate Combined Oral Contraceptives (COCs) in Community-Based Services
NO Please ask the client all of these questions and YES
check the correct box. 1. Is your period late and do you think you could 
be pregnant now? 2. Are you currently breastfeeding a baby under 
6 months of age? 3. Do you smoke cigarettes and are you over 
35 years of age? 4. Do you have repeated severe head pain, often on 
one side or pulsating, causing nausea and made
worse by light, noise, or moving about? 5. Do you have high blood pressure?  6. Have you ever had a stroke, blood clot in your 
legs or lungs, or a heart attack? 7. Do you have diabetes (sugar in your blood)?  8. Do you have or have you had breast cancer?  9. Do you have a serious liver disease or jaundice 
(yellow skin or eyes)? 10. Do you regularly take any pills for tuberculosis 
(TB), fungal infections, or seizures (fits)?
If the client answers NO to all the questions, she can use COCs, but to find out when she can start, continue with question 11.
If the client answers YES to any of the above questions, refer her to the clinic/physician and give her condoms and/or spermicides to use in the meantime.
11. How many days ago did you start your last menstrual period?–# of days
Within last 7 days
If the client began her last menstrual period within the past 7 days, she can start COCs now.
More than 7 days
If the client began her last menstrual period more than 7 days ago, and:
Using Effective Method
If she has been using an effective method of contraception (including abstinence), give her COCs, instruct her to begin taking them now, and instruct her that she must use condoms and/or spermicides or abstain for the next 7 days. Give her condoms and/or spermicides.
Not Using Effective Method
If she has not been using an effective method of contraception (including abstinence), give her the COCs but instruct her to start using them on the first day or during the first 7 days of her next menstrual period. Give her condoms and/or spermicides to use in the meantime.
Pill Effectiveness: Unresolved Issues
No conclusive evidence exists concerning how much antibiotic use, vomiting, and diarrhea–or antibiotics and gastrointestinal illness together–affect the pill’s ability to prevent pregnancy. While imperfect use is the primary reason for pill failure, these other factors are often reported among pill users who become pregnant–usually second to missing pills (47, 207, 253-255, 258, 259). Because some women using OCs report more than one reason for the possible failure of this method, it is difficult to interpret to what extent antibiotic use, vomiting, and diarrhea reduce the pill’s effectiveness.
Only a few drugs are thought to interfere significantly with OC effectiveness (243, 245). Liver enzyme-inducing drugs have been shown to decrease the pill’s effectiveness. These include the antibiotic rifampicin, the antifungal griseofulvin, barbiturates, and anticonvulsants carbamazepine, phenytoin, and primadone (12, 32, 34, 44, 125, 172, 202).
A number of small pharmacologic studies evaluating the effect of broad-spectrum antibiotics on OC effectiveness have found no ovulation among OC users taking these drugs. While in some studies ethinyl estradiol concentrations among women decreased, the level of estrogen remained sufficient to prevent pregnancy (11, 35, 42, 64, 130, 142, 145). Drugs studied include ampicillin, ciprofloxacin, doxycycline, fluconazole, ofloxacin, temafloxacin, tetracycline, and triazole.
Nevertheless, some pill users who became pregnant report taking antibiotics around the time of conception. For example, 21% of women seeking abortions in New Zealand reported taking antibiotics at this time (207). Based on providers’ questioning and assessment, the women in this study are not thought to have missed pills at the time of conception (207). In other studies 4% to as many as 34% of women seeking abortions after OC failure report concurrent antibiotic use, although these studies do not report on other factors that may have played a part in pill failure (47,255).
One reason that concurrent antibiotic use appears to be so common among women experiencing pill failure may be the widespread use of antibiotics: Some women will become pregnant because they missed pills, and, by chance, be using antibiotics at the same time (74).
Other women, however, are affected physiologically by antibiotic use. Some pill users’ bodies absorb less ethinyl estradiol than others. Such women rely on gut flora to consume the ethinyl estradiol and recirculate it through the small intestine. Broad-spectrum antibiotics, however, remove these flora, leaving no mechanism to redistribute the ethinyl estradiol (10, 201). Some researchers conclude that only these women experience pill failure as a result of using antibiotics (10, 201, 234). Unfortunately, there is no way to identify these women in advance (201).
Pill users should not stop taking antibiotics before finishing the full course prescribed to them, even if they are afraid it will make the pill less effective. A growing number of disease organisms are becoming resistant to widely used antibiotics because people are not finishing their full course of antibiotics (257).
Vomiting and Diarrhea
In seven studies of pill users who became pregnant, 19% to 39% reported vomiting, diarrhea, or both in the cycle in which they conceived (47, 207, 253-255, 258, 259). Among abortion-seekers in New Zealand thought not to have missed any pills, 39% reported diarrhea and/or vomiting around the time of conception (207). Similarly, among Danish women experiencing pill failure who had taken all of their pills, 23% reported gastroenteritis around the time of conception (253).
Vomiting and diarrhea can interfere with absorption of both estrogen and progestin. Although the hormones in OCs are absorbed in the upper intestinal tract, the increased movement of the intestines during bouts of illness seems to reduce hormonal absorption (63). Many pill users, however, are not aware that vomiting and/or diarrhea may make the pill less effective (19, 47).
What Advice to Give?
No consensus exists on how to advise pill users. Some recommendations suggest added protection during these times, while others do not consider it necessary.
Among the advice that has been offered are the following:
* Pill users taking broad-spectrum antibiotics do not need to use a back-up method, since pharmacological studies do not show an increased risk of pill failure (84).
* Pill users can use an additional method of contraception if they want extra protection from pregnancy (7, 234, 241).
* Pill users can omit the seven-day hormone-free interval between pill packs while taking antibiotics (72).
* Long-term users of antibiotics can increase their contraceptive protection by switching to higher-dose pills, such as those containing 50 [micro]g of ethinyl estradiol (72).
* Women with illnesses causing vomiting and/or diarrhea can use an additional method or abstain from sexual intercourse for 7 to 14 days after the illness (85, 120, 135, 194, 206).
* Women should take another pill if vomiting or diarrhea occurs within two hours after taking a pill. Two hours is sufficient time for the hormones in the pill to be absorbed and maintain contraceptive effectiveness (8).
(*) Unless noted otherwise, the term “OCs” as used in this report indicates combined oral contraceptives. Most studies of typical use, however, do not specify whether rates are for progestin-only pills, combined OCs, or both. Since most pill users take combined OCs, it can be assumed that these data largely reflect rates for combined pills.
An asterisk (*) denotes an item that was particularly useful in the preparation of this issue of Population Reports.
(1.) ADINMA, J.I. and OKEKE, A.O. The pill: Perceptions and usage among Nigerian students. Advances in Contraception 9(4): 341-349. Dec. 1993.
(2.) AKHTER, H. A special obligationAccess to contraception. Network 13(3): 4-5. Research Triangle Park, North Carolina, Family Health International. Mar. 1993.
(3.) AKHTER, H.H., CHOWDHURY, M.E.E.K., RAHMAN, M.H., and HUSSAIN, M.A.I. Report on a study to compare compliance, continuation and failure rates and reported side effects of low dose and standard dose oral pill in rural Bangladesh. Dhaka, Bangladesh Institute of Research for Promotion of Essential and Reproductive Health and Technologies, Apr. 1996. 110 p.
(*)(4.) ALI, M. and CLELAND, J. Contraceptive discontinuation in six developing countries: A cause-specific analysis. International Family Planning Perspectives 21 (3): 92-97. Sep. 1995.
(5.) ALI, N., WELLS, E., and SUTTON, D. Reviewing print material for oral contraceptives: Direction for the future. Washington, D.C., Program for Appropriate Technology in Health, Jul. 9, 1998. 70 p.
(6.) AMERICAN HEALTH CONSULTANTS (AHC). Prepare family planning patients for successful pill-taking. Contraceptive Technology Update 19(4): 45-47. Atlanta, Georgia, AHC. Apr. 1998.
(7.) ANGLE, M., HUFF, P.S., and LEA, J.W. Interactions between oral contraceptives and therapeutic drugs. Outlook 9(1): 1-6. Apr. 1991.
(8.) ANGLE, M. (INTRAH/PRIME) [Making up missed pills] Personal communication, Jun. 2000.
(9.) ARMSTRONG, J.L., REID, M., and BIGRIGG, A. Scare over oral contraceptives. Effect on behaviour of women attending a family planning clinic [letter]. British Medical Journal 311 (7020): 1637. Dec. 16, 1995.
(10.) BACK, D.J. and ORME, M.L. Pharmacokinetic drug interactions with oral contraceptives. Clinical Pharmacokinetics 18(6): 472-484. Jun. 1990.
(11.) BACK, D.J., TIJA, J., MARTIN, C., MILLAR, E., MANT, T., MORRISON, P., and ORME, M. The lack of interaction between temafloxacin and combined OC steroids. Contraception (43): 317-323. 1991.
(12.) BARDITCH-CROVO, P., TRAPNELL, C.B., ETTE, E., ZACUR, H.A., CORESH, J., ROCCO, L.E., HENDRIX, C.W., and FLEXNER, C. The effects of rifampicin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clinical Pharmacology and Therapeutics 65(4): 428-438. 1999.
(13.) BARNETT, B. Fertility awareness benefits couples. Network 17(1): 4-8. Family Health International. Fall 1996.
(14.) BARNETT, B. Zimbabwe’s “clinics under trees” increase access. Network 17(2): 15-16. Family Health International. Spring 1999.
(15.) BEKSINSKA, M.E., REES, V.H., NKONYANE, T., and MCINTYRE, J.A. Compliance and use behaviour, an issue in injectable as well as oral contraceptive use? A study of injectable and oral contraceptive use in Johannesburg. British Journal of Family Planning 24(1): 21-23. Apr. 1998.
(16.) BLACKBURN, R., CUNKELMAN, J.A., and ZLIDAR, V.M. Oral contraceptives: An update. Population Reports, Series A, No. 9. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Spring 2000. 39 p.
(17.) BORODITSKY, R., FISHER, W., and SAND, M. The 1995 Canadian Contraception Study. Journal of the Society of Obstetricians and Gynecologists of Canada (Special Suppl.): 1-31. Dec. 1996.
(18.) BRADLEY, J. Using COPE to improve quality of care: The experience of the Family Planning Association of Kenya. Quality/Calidad/Qualite No. 9. Population Council, 1998. p. 1-24.
(19.) BROMHAM, D.R. and CARTMILL, R.S.V. Knowledge and use of secondary contraception among patients requesting termination of pregnancy. British Medical Journal 306(6877): 556-557. Feb. 27, 1993.
(20.) BROOK, S.J. and SMITH, C. Do combined oral contraceptive users know how to take their pills correctly? British Journal of Family Planning 17(1): 18-20. Apr. 1991.
(21.) CANALES, J.R.L., CARCAMO, J.A., GALINDO, J., VERNON, R., and BRAMBILA, C. Reproductive health and prenatal care. Washington, D.C., Population Council, Apr. 30, 1995. (INOPAL II: Final technical report) 74 p. (Unpublished).
(22.) CASTLE, S., KONATE, M.K., ULIN, P.R., and MARTIN, S. Clandestine contraceptive use in urban Mall. Studies in Family Planning 30(3): 231-248. Sep. 1999.
(23.) CENTRAL BUREAU OF STATISTICS, STATE MINISTRY OF POPULATION/NATIONAL FAMILY PLANNING COORDINATION BOARD, MINISTRY OF HEALTH, and MACRO INTERNATIONAL (MI). Indonesia Demographic and Health Survey, 1994. Calverton, Maryland, MI, Oct. 1995. 366 p.
(24.) CENTRAL BUREAU OF STATISTICS, STATE MINISTRY OF POPULATION/NATIONAL FAMILY PLANNING COORDINATION BOARD, MINISTRY OF HEALTH, AND MACRO INTERNATIONAL (MI). Indonesia Demographic and Health Survey, 1997. Calverton, Maryland, MI, Oct. 1998. 324 p.
(25.) CHASAN-TABER, L., WlLLETT, W.C., STAMPFER, M.J., HUNTER, D.J., COLDITZ, G.A., SPIEGELMAN, D., and MANSON, J.E. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20(3): 330-335. Mar. 1997.
(26.) CHILD, T.J., MACKENZIE, I.Z., and REES, M. Terminations of pregnancy, not unplanned deliveries, increased as result of pill scare [letter]. British Medical Journal 313(7063): 1005. Oct 19, 1996.
(27.) CHILD, T.J., REES, M., and MACKENZIE, I.Z. Pregnancy terminations after oral contraception scare [letter]. Lancet 347(9010): 1260-1261. May 4, 1996.
(28.) COEYTAUX, F.M. and ALLINA, A. The pill without prescription: The international experience. In: Samuels, S.E. and Smith, M.D., eds. The Pill: From Prescription to Over the Counter. Menlo Park, California, Kaiser Family Foundation. 1994. p. 41-51.
(29.) COGGINS, C., LANGER, A., WINIKOFF, B., LAZCANO, E.C., HEIMBURGER, A., and SLOAN, N. Effectiveness of integration of self-screening of STDs into family planning programs. Presented at the American Public Health Association 126th Annual Meeting, Washington, D.C., Nov 15-18, 1998.
(30.) CNN. No prescription for the Pill? FDA considers making the pill available over-the-counter. CNN.com. Jun. 29, 2000.
(31.) CONNELL, E.B. Patient counseling. Advances in Contraception 8(Suppl. 1): 67-73. Oct. 1992.
(32.) COTE, J. Interaction of griseofulvin and oral contraceptives. Journal of the American Academy of Dermatology 22(1): 124-125. Jan. 1990.
(33.) COTTEN, N., STANBACK, J., MAIDOUKA, H., TAYLOR-THOMAS, J.T., and TURK, T. Early discontinuation of contraceptive use in Niger and The Gambia. International Family Planning Perspectives 18(4): 145-149. Dec. 1992.
(34.) CRAWFORD, P., CHADWICK, D.J., MARTIN, C., TJIA, J., BACK, D.J., and ORME, M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. British Journal of Clinical Pharmacology 30(6): 892-896. Dec. 1990.
(35.) CSEMICZKY, G., ALVENDAL, C., and LANDGREN, B.M. Risk for ovulation in women taking a low-dose OC (Microgynon) when receiving antibacterial treatment with fluoroquinolone (ofloxacin). Advances in Contraception 12(2): 101-109. Jun. 1996.
(36.) CURTIS, S.L. and BLANC, A.K. Determinants of contraceptive failure, switching and discontinuation: An analysis of DHS contraceptive histories. Calverton, Maryland, Macro International, Oct. 1997. (DHS Analytical Reports No. 6) 50 p.
(37.) DARNEY, P.D. OC practice guidelines: Minimizing side effects. International Journal of Fertility and Women’s Medicine 42(Suppl. 1): 158-169.1997.
(38.) DAVIS, A. and WYSOCKI, S. Clinician/patient interaction: Communicating the benefits and risks of oral contraception. Contraception 59(1 Suppl.): 39S-42S. Jan. 1999.
(39.) DE BOER, A. and HERINGS, R.M. Oral contraceptives without prescription [letter]. Lancet 342(8877): 993. Oct. 16, 1993.
(40.) DEIJEN, J.B. and KORNAAT, H. The influence of type of information, somatization, and locus of control on attitude, knowledge, and compliance with respect to the triphasic oral contraceptive Tri-Minulet. Contraception 56(1): 31-41. Jul. 1997.
(41.) DEPARTMENT OF NATIONAL HEALTH AND POPULATION DEVELOPMENT, S.A. Annual report on family planning statistics 1992-1993. Department of National Health and Population Development, South Africa, 1993.
(42.) DEVENPORT, M.H., CROOK, D., WYNN, V., and LEES, L.J. Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives. British Journal of Clinical Pharmacology (27): 851-859.1989.
(43.) DILLNER, L. Pill scare linked to rise in abortions. British Journal of Medicine 312(7037): 996. Apr. 20, 1996.
(44.) DONLEY, T.G., SMITH, R.F., and ROY, B. Reduced oral contraceptive effectiveness with concurrent antibiotic use: A protocol for prescribing antibiotics to women of childbearing age. Compendium 11(6): 392-396. Jun. 1990.
(45.) DOUCOURE, A., DJENEBA, D., TOURE, F., TRAORE, A., DOUMBIA, S., SANOGO, D., HUNTINGTON, D., and VIADRO, C. The effect of a family planning CBD project in Mall. In: Foreit, J.R. and Frejka, T., eds. Family Planning Operations Research: A Book of Readings. New York, Population Council. 1998. p. 115-120.
(46.) DRENNAN, M. Reproductive health: New perspectives on men’s participation. Population Reports, Series J, No. 46. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Oct. 1998. 36 p.
(47.) DUNCAN, G., HARPER, C., ASHWELL, E., MANT, D., BUCHAN, H., and JONES, L Termination of pregnancy: Lessons for prevention. British Journal of Family Planning 15(4): 112-117. Jan. 1990.
(48.) ELOMAA, K., ROLLAND, R., BROSENS, I., MOORREES, M., DEPREST, J., TUOMINEN, J., and LAHTEENMAKI, R Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation. American Journal of Obstetrics and Gynecology 179(1): 41-46. Jul. 1998.
(49.) ENTWISLE, B., RINDFUSS, R.R., WALSH, S.J., EVANS, T.P., and CURRAN, S.R. Geographic information systems, spatial network analysis, and contraceptive choice. Demography 34(2): 171-187. May 1997.
(50.) ENUNLU, T. and DOGAN, B.G. Contraceptive use dynamics in Turkey. In: Akin, A. and Bertan, M., eds. Contraception, Abortion, and Maternal Health Services in Turkey: Results of Further Analysis of the 1993 Turkish Demographic and Health Survey. 1996. Calverton, Maryland, Macro International. p. 13-65.
(51.) FAMILY HEALTH INTERNATIONAL (FHI). Checklist for clients who want to initiate combined oral contraceptives (COCs) in community-based services (CBS). FHI (Website). http://www.fhi.or g/en/fp/checklistse/chklstfpe/cocchkl.html. Oct 8, 1999.
(52.) FAMILY HEALTH INTERNATIONAL (FHI). Checklist to rule out pregnancy for non-menstruating family planning clients. FHI (Website). http://www.fhi.org/en/fp/checklistse/chklstfpe/pregckl .html. Oct 8, 1999.
(53.) FAMILY HEALTH INTERNATIONAL (FHI). Pregnancy-related morbidities affect millions. Research Triangle Park, North Carolina, FHI, Feb. 15, 1994. 2 p.
(54.) FAMILY PLANNING LOGISTICS MANAGEMENT (FPLM)/JOHN SNOW, INC. (JSI). Programs that deliver: Logistics’ contributions to better health in developing countries. Arlington, Virginia, FPLM/JSI, 2000. 117 p.
(55.) FAMILY PLANNING NEWS. Assurance on safety of contraceptive pill: Weighed in the balances–And found beneficial. Family Planning News, Vol. 21 No. 2. 1996. p. 4. (Report on the 4th Congress of the European Society of Contraception, Barcelona, Italy)
(56.) FAMILY PLANNING SERVICE EXPANSION AND TECHNICAL SUPPORT (SEATS II) Project. Mainstreaming quality improvement in family planning and reproductive health services delivery: Context and case studies. Arlington, Virginia, John Snow, Inc., Jan. 2000. 93 p.
(57.) FARRELL, B., SOLTER, C., and HUBER, D. Comprehensive reproductive health and family planning training curriculum: Module 5: Emergency contraceptive pills. Pathfinder International (Website). http://www.pathfind.org/html/mod_links.htm. Nov. 1997.
(58.) FATHONAH, S. Contraceptive use dynamics in Indonesia. Calverton, Maryland, Macro International, Jul. 1996. (Demographic and Health Surveys Working Paper No. 20) 31 p.
(59.) FINGER, W.R. Using oral contraceptives correctly: Progress on package instructions. Network 12(2): 14-17, 27. Research Triangle Park, North Carolina, Family Health International. Sep. 1991.
(60.) FINGER, W.R. Oral contraceptives are safe, very effective. Network 16(4): 4-8. Research Triangle Park, North Carolina, Family Health International. Summer 1996.
(61.) FINGER, W.R. Commercial sector can improve access. Network 18(2): 12-15. Research Triangle Park, North Carolina, Family Health International. Winter 1998.
(*)(62.) FONTAINE, A., POTTER, L., and VENEY, J.E. Use-effectiveness of oral contraceptives and quality of care. Apr. 25, 1993. 28 p. (Unpublished).
(63.) FOTHERBY, K. Interactions with oral contraceptives. American Journal of Obstetrics and Gynecology 163(6 Pt. 2): 2153-2159. Dec. 1990.
(64.) FRIEDMAN, C.I., HUNEKE, A.L., KIM, H.M., and POWELL, J. The effect of ampicillin on oral contraceptive effectiveness. Obstetrics and Gynecology (164): 33-37.1980.
(65.) GANDOTRA, M.M. and DAS, N.P. Factors influencing choice of a contraceptive and the reasons for its discontinuation. In: Khan, M.E. and Cernada, G., eds. Spacing as an Alternative Strategy: India’s Family Welfare Programme. New Delhi, BR Publishing Corporation. 1996. p. 95-114.
(66.) GARG, S.K., CHASE, H.P., MARSHALL, G., HOOPS, S.L, HOLMES, D.L., and JACKSON, W.E. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. Journal of the American Medical Association 271(14): 1099-1102. Apr. 13, 1994.
(67.) GLASIER, A. Safety of emergency contraception. Journal of the American Medical Women’s Association 53(5): 219-221. Fall 1998.
(68.) GRIFFEY BRECHIN, S.J., SULLIVAN, R., SMITH, T., and LACOSTE, M. Improving performance of healthcare providers through structured on-the-job training: A pilot test in Zimbabwe and Kenya. Baltimore, Johsn Hopkins International Education and Training in Reproductive Health, Mar. 1999. (No. JHP-04) 32 p.
(69.) GRIMES, D.A. Over-the-counter oral contraceptives–An immodest proposal? [editorial]. American Journal of Public Health 83(8): 1092-1094. Aug. 1993.
(70.) GRIMES, D.A. A guest editorial: Over-the-counter oral contraceptives: An idea whose time has not quite come [editorial]. Obstetrical and Gynecological Survey 50(6): 411-412. Jun. 1995.
(71.) GUILLEBAUD, J. Practical prescribing of the combined oral contraceptive pill. Unpublished, 1989.25 p.
(*)(72.) GUILLEBAUD, J. The Pill. 5th ed. London, Oxford Univ. Press, 1997. 288 p.
(*)(73.) GUILLEBAUD, J. The Pill and Other Forms of Hormonal Contraception. 5th ed. Oxford, Oxford University Press, 1997.320 p.
(74.) GUILLEBAUD, J. (Margaret Pyke Family Planning Centre) [Comments on draft report, “Helping women use the pill”] Personal communication, May 24, 2000.
(75.) GUILLEBAUD, J. Contraception Today: A pocketbook for General Practitioners. 4th ed. London, Martin Dunitz, Jun. 2000. 120 p.
(76.) GUILLEBAUD, J. Will the pill become obsolete in this century? Family Planning Perspectives 32(2): 93-95. Mar/Apr. 2000. (Available: http://www.agi-usa.org/pubs/journals/3209300.html#1)
(77.) GUPTA, A., CHOUDHURY, B.R., and BALACHANDRAN, I. Touch me, touch-me-not: Women, plants and healing. In: Women’s Beliefs about Disease and Health: Kali for Women. 1997. p. 66-91.
(78.) HA, P.T.T., HANH, L.T., DUNG, N.T.K., SA, N.T., and SCHULER, S.R. Reproductive tract infections and contraceptive method choice: Findings from a qualitative study in Vietnam. 1999. 18 p. (Unpublished).
(79.) HALPERIN, E.C. Oral contraceptives as over-the-counter medication. North Carolina Medical Journal 55(5): 183-186. May 1994.
(80.) HARDEE, K., CLYDE, M., MCDONALD, O.P., BAILEY, W., and VILLINSKI, M.T. Assessing family planning service-delivery practices: The case of private physicians in Jamaica. Studies in Family Planning 26(6): 338-349. Nov./Dec. 1995.
(81.) HARDEE, K., JANOWITZ, B., STANBACK, J., and VILLINSKI, M.T. What have we learned from studying changes in service delivery guidelines and practices? International Family Planning Perspectives 24(2): 84-90. Jun. 1998. (Available: http://www.agi-us a.org/pubs/journals/2408498.html, Accessed Aug. 13, 1999)
(82.) HARVEY, P.D. 1991 Contraceptive social marketing statistics. Washington, D.C., DKT International, Jun. 1992.6 p.
(83.) HARVEY, P.D. 1998 Contraceptive social marketing statistics. Washington, D.C., DKT International, Sep. 1999.8 p.
(*)(84.) HATCHER, R.A. and GUILLEBAUD, J. The pill: Combined oral contraceptives. In: Hatcher, R.A., Trussell, J., Stewart, F., Cares Jr., W., Stewart, G.K., Guest, F., and Kowal, D. Contraceptive Technology. 17th ed. New York, Ardent Media. 1998. p. 405-466.
(*)(85.) HATCHER, R.A., RINEHART, W., BLACKBURN, R., GELLER, J.S., and SHELTON, J.D. The Essentials of Contraceptive Technology. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Jul. 1997. 340 p.
(86.) HAVANON, N., KANCHANASINITH, K., POTTER, L., and CANAMAR, R. Thailand: Study of pill compliance among drugstore purchasers. Bangkok, Oct. 1992.42 p.
(87.) HELZNER, J.F., CARAM, M., CORDERO, M., and SANGIOVANNI, G. Assessing strategies to promote high quality care: The case of PROFAMILIA, Dominican Republic. Presented at the American Public Health Association 118th Annual Meeting, New York, Sep. 30-Oct. 4, 1990. International Planned Parenthood Federation, PROFAMILIA. Oct. 1990. 10 p.
(88.) HILLARD, P.J. Oral contraception noncompliance: The extent of the problem. Advances in Contraception 8(Suppl. 1): 13-20. Oct. 1992.
(89.) HILLARD, P.J. Family planning in the teen population. Current Opinion in Obstetrics and Gynecology 5(6): 798-804. Dec. 1993.
(90.) HODGINS, S. Contraceptive use and beliefs among women in rural Togo. 1999.
(91.) HOSSAIN, M.B. and PHILLIPS, J.F. The impact of outreach on the continuity of oral contraceptive use in rural Bangladesh. Studies in Family Planning 27(2): 98-106. Mar/Apr. 1996.
(92.) HOUGHTON, A. Oral contraceptives without prescription [letter]. Lancet 342(8877): 993. Oct. 16, 1993.
(93.) HUBACHER, D., GOCO, N., GONZALEZ, B., and TAYLOR, D. Factors affecting continuation rates of DMPA. Contraception 60(345-351). 1999.
(*)(94.) HUBACHER, D. and POTTER, L. Adherence to oral contraceptive regimens in four countries. International Family Planning Perspectives 19(2): 49-53. Jun. 1993.
(95.) HUEZO, C. and CARIGNAN, C.S. Medical and service delivery guidelines for family planning. 2nd ed. International Planned Parenthood Federation (IPPF) Medical Publications. London, IPPF, World Health Organization, and AVSC International, 1997.298 p.
(96.) HUEZO, C. and MALHOTRA, U. Choice and use-continuation of methods of contraception: A multicentre study. London, International Planned Parenthood Federation, 1993. 163 p.
(97.) HUNTINGTON, D. and APLOGAN, A. The integration of family planning and childhood immunization services in Togo. Studies in Family Planning 25(3): 176-183. May/Jun. 1994.
(98.) HUNTINGTON, D., HASSAN, E.O., ATTALLAH, N., TOUBIA, N., NAGUIB, M., and NAWAR, L. Improving the medical care and counseling of postabortion patients in Egypt. Studies in Family Planning 26(6): 350-362. Nov./Dec. 1995.
(99.) INDONESIA NATIONAL FAMILY PLANNING COORDINATING BOARD (BKKBN). The operational aspect of population and family planning program implementation. BKKBN (Website). http://www.bkkbn.go.id/english/c.htm. Undated.
(100.) INTERNATIONAL WORKING GROUP ON ENHANCING PATIENT COMPLIANCE AND ORAL CONTRACEPTIVE EFFICACY. A consensus statement: Enhancing patient compliance and oral contraceptive efficacy. British Journal of Family Planning (18): 126-129. 1993.
(101.) IVERSEN, O.E. and NILSEN, S.T. The recent pill scare and number of legal abortions in Norway. Acta Obstetricia et Gynecologica Scandinavica 75(7): 690-691. Aug. 1996.
(102.) JAIN, A. Should eliminating unmet need for contraception continue to be a program priority? International Family Planning Perspectives 25(Suppl.): S39-S43, S49. Jan. 1999.
(103.) JOHNS HOPKINS CENTER FOR COMMUNICATION PROGRAMS/POPULATION COMMUNICATION SERVICES (JHU/PCS). New research documents success of Johns Hopkins GATHER counseling for family planning. JHU/PCS (Website). http://www.jhuccp.org/news/020899.stm. Feb. 8, 1999.
(104.) JOHNS HOPKINS CENTER FOR COMMUNICATION PROGRAMS/POPULATION COMMUNICATION SERVICES (JHU/PCS). Nepal’s radio communication project. JHU/PCS (Website). http://www.jhuccp.org/ee/jan14.stm. 2000.
(105.) JOHNS HOPKINS CENTER FOR COMMUNICATION PROGRAMS/POPULATION COMMUNICATION SERVICES (JHU/PCS). Scripts from Nepal radio show, “Cut Your Coat According to Your Cloth.” Baltimore, JHU/PCS, 2000.
(106.) JOHNS HOPKINS CENTER FOR COMMUNICATION PROGRAMS/POPULATION COMMUNICATION SERVICES (JHU/PCS). Scripts from Nepal radio show, “Service Brings Rewards.” Baltimore, JHU/PCS, 2000.
(107.) JOHNS HOPKINS PROGRAM FOR INTERNATIONAL TRAINING IN REPRODUCTIVE HEALTH (JHPIEGO). Performance improvement process. JHPIEGO (Website). http://www.reproline.j hu.edu/english/3improve/3process/3pi.htm. Jan. 20, 1999.
(108.) JONES, E.F. Accessibility as a determinant of contraceptive method choice. In: Bulatao, R.A., Palmore, J.A., and Ward, S.E., eds. Choosing a Contraceptive: Method Choice in Asia and the United States. Boulder, Colorado, Westview Press. 1989; p. 57-77.
(109.) KANE, T.T., GAMINIRATNE, K.H.W., and STEPHEN, E.H. Contraceptive method switching in Sri Lanka: Patterns and implications. International Family Planning Perspectives 14(2): 68-75. Jun. 1988.
(110.) KELLER, S. Better communication improves OC use. Network 16(4): 10-13. Research Triangle Park, North Carolina, Family Health International. Summer 1996.
(111.) KILLICK, S.R. Patient education and understanding: A critical review. Advances in Contraception 8(Suppl. 1): 57-65. Oct. 1992.
(112.) KILLICK, S.R., BANCROFT, K., OELBAUM, S., MORRIS, J., and ELSTEIN, M. Extending the duration of the pill-free interval during combined oral contraception. Advances in Contraception 6(1): 33-40. Mar. 1990.
(113.) KINCAID, D.L. Social networks, ideation, and contraceptive behavior in Bangladesh: A longitudinal analysis. Social Science and Medicine 50(2): 215-231. Jan. 2000.
(114.) KNAUFF, J., MUHUHU, P., and YUMKELLA, F. Improving service access in the mountains of the moon. Chapel Hill, North Carolina, Program for International Training in Health, 1994. 6 p.
(115.) KNOWLES, J. and RINGEL, M. All About Birth Control: The Complete Guide. Issued by Planned Parenthood Federation of America. New York, Three Rivers Press, 1998. 240 p.
(116.) KOLS, A. and SHERMAN, J.E. Family planning programs: Improving quality. Series J, No. 47. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Nov. 1998. 40 p.
(117.) KONTULA, O. and HAAVIO-MANNILA, E. Finland. In: Francoeur, R.T., ed. The International Encyclopedia of Sexuality. Vol. 1. New York, Continuum. 1997. p. 419-491.
(*)(118.) KORVER, T., GOORISSEN, E., and GUILLEBAUD, J. The combined oral contraceptive pill: What advice should we give when tablets are missed? British Journal of Obstetrics and Gynaecology 102(8): 601-607. Aug. 1995.
(119.) KOST, K. The dynamics of contraceptive use in Peru. Studies in Family Planning 24(2): 109-119. Mar./Apr. 1993.
(120.) KOVACS, G.T. and MURTAGH, J. Survey of general practitioner instructions to oral contraceptive users. Australian Family Physician 23(5): 915-918. May 1994.
(121.) LANDGREN, B.M. and CSEMICZKY, G. The effect on follicular growth and luteal function of “missing the pill.” A comparison between a monophasic and a triphasic combined oral contraceptive. Contraception 43(2): 149-159. Feb. 1991.
(122.) LANDGREN, B.M. and DICZFALUSY, E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Contraception 29(5): 437-446. 1984.
(123.) LARSON, A., ISLAM, S., and MITRA, S.N. Pill use in Bangladesh: Compliance, continuation and unintentional pregnancies. Report on the 1990 pill use study. Dhaka, Mitra and Associates, Jul. 1991.70p.
(124.) LAWRENCE, H. How early-cycle side effects discourage pill use. Contemporary Ob/Gyn 42(9): 45-49, 52, 55-59. SOP. 1997.
(125.) LEBEL, M., MASSON, E., GUILBERT, E., COLBORN, D., PAQUET, F., ALLARD, S., VALLEE, F., and NARANG, P.K. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. Journal of Clinical Pharmacology 38(11): 1042-1050. Nov. 1998.
(126.) LEI, Z.-W., WU, S.C., GARCEAU, R.J., JIANG, S., YANG, Q.-Z., WANG, W.-L, and VANDER MEULEN, T.C. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception (53): 357-361. 1996.
(127.) LETTERIE, G.S. and CHOW, G.E. Effect of “missed” pills on oral contraceptive effectiveness. Obstetrics and Gynecology 79(6): 979-982. Jun. 1992.
(128.) LEWIS, G.L. and LISKIN, L.S. Perceptions of oral contraceptives: Pretest results of new package label. Baltimore, Johns Hopkins School of Public Health, Population Communication Services, May 1997. 111 p.
(129.) LOZA, S.F., SAYED, H.A.A., and POTTER, L.S. Oral contraceptive compliance and continuation in Egypt: Complementary findings of EDHS (1988) and focus group research. Cairo, Cairo Demographic Center, 1991. (Working Paper No. 22) 24 p.
(130.) MAGGIOLI, F., PURICELLI, G., DOTTORINI, M., CAPRIOLI, S., BIANCHI, W., and SUTER, F. The effect of ciprofloxacin on oral contraceptive steroid treatments. Drugs Under Experimental and Clinical Research 17(9): 451-454. 1991.
(131.) MANAGEMENT SCIENCES FOR HEALTH (MSH) FAMILY PLANNING MANAGEMENT DEVELOPMENT, ED. MILLER, J., SERIES ED. Improving contraceptive supply management. Family Planning Manager, Boston, MSH, Vol. 1 Sep/Oct. 1992. 20 p.
(132.) MCCAULEY, A., ROBEY, B., BLANC, A., and GELLER, J. Opportunities for women through reproductive choice. Population Reports, Series M, No. 12. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Jul. 1994. 39 p.
(133.) MELIAN, M.M. La dinamica del uso de la anticoncepcion en Paraguay: Un analisis de discontinuacion, falla, y cambio de metodos con tablas de vida. [SPA] [Contraceptive use dynamics in Paraguay: A life-table analysis of discontinuation, failure, and switching]. Calverton, Maryland, Macro International, Jun. 1994. (Seminario sobre la Dinamica Anticonceptiva en America Latina)
(134.) MENSCH, B.S., BRUCE, J., and GREENE, M.E. The uncharted passage: Girls’ adolescence in the developing world. Population Council, 1998. 115 p.
(135.) MILLER, C. The combined oral contraceptive. A practical guide. Australian Family Physician 19(6): 897, 900-906. Jun. 1990.
(136.) MILLER, C. and MURTAGH, J. Combined oral contraception. Australian Family Physician 21(12): 1787-1788. Dec. 1992.
(137.) MILLER, K., MILLER, R., and FASSIHIAN, G. How do providers restrict access to family planning methods? Population Council, 1998, (Unpublished).
(138.) MILLER, K., MILLER, R., and KOTKIN, D.J. Quality of care in African family planning programs: A survey of findings from situation analysis studies. New York, Population Council, Sep. 1995. 19 p.
(139.) MITRA, S.N. and AL-SABIR, A. Contraceptive use dynamics in Bangladesh. Calverton, Maryland, Macro International, Oct. 1996. (DHS Working Papers No. 21) 28 p.
(140.) MOLLOY, B.G., COULSON, K.A., LEE, J.M., and WATTERS, J.K. “Missed pill” conception: Fact or fiction? British Journal of Medicine 290(6480): 1474-1475. May 18, 1985.
(*)(141.) MORENO, L. and GOLDMAN, N. Contraceptive failure rates in developing countries: Evidence from the Demographic and Health Surveys. International Family Planning Perspectives 17(2): 44-49. Jun. 1991.
(142.) MURPHY, A.A., ZACUR, H.A., CHARACE, P., and BURKMAN, R.T. The effect of tetracycline on level of oral contraceptives. American Journal of Obstetrics and Gynecology (164): 28-33. 1991.
(143.) MURPHY, E. and STEELE VERME, C. Client-provider interactions in family planning services: Guidance from research and program experience. In: Technical Guidance/Competence Working Group. Recommendations for updating selected practices in contraceptive use: Volume II. Chapel Hill, North Carolina, Sep. 1997. p. 187-194.
(144.) MURRAY, C.J.L and LOPEZ, A.D. The global burden of disease in 1990s: Final results and their sensitivity to alternative epidemiological perspectives, discount rates, age-wights, and disability weights. In: Murray, C.J.L and Lopez, A.D., eds. The Global Burden of Disease. The Global Burden of Disease and Injury Series. Vol. 1. Boston, Massachusetts, Harvard University Press. 1996. p. 247-293.
(145.) NEELY, J.L., ABATE, M., SWINKER, M., and D’ANGIO, R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstetrics and Gynecology 77(3): 416-420. Mar. 1991.
(*)(146.) OAKLEY, D. Rethinking patient counseling techniques for changing contraceptive use behavior. American Journal of Obstetrics and Gynecology 170(3, Pt. 2): 1585-1590. May 1994.
(147.) OAKLEY, D., POTTER, L., DE LEON-WONG, E., and VISNESS, C. Oral contraceptive use and protective behavior after missed pills. Family Planning Perspectives 29(6): 277-279, 287. Nov./Dec. 1997.
(148.) OAKLEY, D., SEREIKA, S., and BOGUE, E.L. Oral contraceptive pill use after an initial visit to a family planning clinic. Family Planning Perspectives 23(4): 150-154. Jul./Aug. 1991.
(149.) ORDONEZ GOMEZ, M. La dinamica anticonceptiva en Colombia: discontinuacion del uso de metodos anticonceptivos, cambio y tasas de falla de los metodos. [SPA] [Contraceptive dynamics in Colombia: discontinuation of contraceptive methods, change, and failure rates]. Calverton, Maryland, Macro International, Jun. 1994. (Seminario sobre la Dinamica Anticonceptiva en America Latina) 26 p.
(150.) OSLER, M. and RIPHAGEN, F.E. Contraception survey: Denmark 1988. Contraception 42(5): 507-521. Nov. 1990.
(151.) OTTOLENGHI, E. (Population Council) [Increasing pill access] Personal communication, May 15, 2000.
(152.) PADILLA, A. La dinamica del uso de la anticoncepcion en el Peru: Un analisis de discontinuacion, falla, y cambio de metodos. [SPA] [Contraceptive use dynamics in Peru: An analysis of discontinuation, failure, and switching]. Calverton, Maryland, Macro International, Jun. 1994. (Seminario sobre la Dinamica Anticonceptiva en America Latina)
(153.) PEREZ, A. and TABIJE, T.L. Contraceptive discontinuation, failure, and switching behavior in the Philippines. Calverton, Maryland, Macro International, Apr. 1996. (DHS Working Papers No. 18) 25 p.
(154.) PETERSEN, K.R., SKOUBY, S.O., SIDELMANN, J., MOLSTEDPEDERSEN, L., and JESPERSEN, J. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. American Journal of Obstetrics and Gynecology 171(2): 400-405. Aug. 1994.
(155.) PHILLIPS, J.F., HOSSAIN, M.B., and ARENDS-KUENNING, M. The long-term demographic role of community-based family planning in rural Bangladesh. Studies in Family Planning 27(4): 204-219. Jul./Aug. 1996.
(156.) PIOTROW, P., KINCAID, D.L, RiMON III, J., and RINEHART, W. Health Communication: Lessons From Family Planning and Reproductive Health. Westport, Connecticut, Praeger, 1997.307 p.
(157.) PIOTROW, P.T. Informed choice: A responsibility that goes beyond the provider. In: Gallen, M.A., Lettenmaier, C., and Green, C. R Counseling makes a difference. Population Reports, Series J, No. 35. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Nov. 1987. p. 15.
(158.) PIOTROW, P.T., TREIMAN, K.A., RIMON III, J.G., YUN, S.H., and LOZARE, B.V. Strategies for family planning promotion. Washington, D.C., World Bank, 1994. (World Bank Technical Paper No. 223) 58 p.
(159.) POLANCO, J.J. La dinamica de uso de anticoncepcion en la Republica Dominicana: Un analisis de discontinuacion, falla, y cambio de metodos. [SPA] [Contraceptive use dynamics in the Dominican Republic: An analysis of discontinuation, failure, and switching]. Calverton, Maryland, Macro International, Jun. 1994. (Seminario sobre la Dinamica Anticonceptiva en America Latina)
(160.) POPULATION COUNCIL (PC). A situation analysis of family welfare centers in Pakistan. New York, PC, Apr. 1993.92 p.
(161.) POPULATION COUNCIL (PC). A situation analysis of family planning service delivery points in Ghana. New York, PC, 1994.150 p.
(*)(162.) POPULATION COUNCIL (PC). The gap between reproductive intentions and behavior: A study of Punjabi men and women. Islamabad, Pakistan, PC, 1997.78 p.
(*)(163.) POTTER, L.S. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer, J.A. and Spilker, B., eds. Patient Compliance in Medical Practice and Clinical Trials. New York, Raven Press. 1991. p. 195-207.
(*)(164.) POTTER, L.S. How effective are contraceptives? The determination and measurement of pregnancy rates. Obstetrics and Gynecology 88(3 Suppl.): 13S-23S. Sep. 1996.
(165.) POTTER, L.S., OAKLEY, D., DE LEON-WONG, E., and CANAMAR, R. Measuring compliance among oral contraceptive users. Family Planning Perspectives 28(4): 154-158. Jul./Aug. 1996.
(*)(166.) POTTER, L.S., POTTS, M., GRUBB, G., and STEINER, M. What do we know about how women take the pill? 1991.41 p. (Unpublished).
(167.) POTTS, M. and DENNY, C. Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status. Drug Safety 13(6): 333-337. Dec. 1995.
(168.) PRATT, W.F. and BACHRACH, C.A. What do women use when they stop using the pill? Family Planning Perspectives 19(6): 257-266. Nov./Dec. 1987.
(169.) PULLAM, T.W. The relationship of service availability to contraceptive use in rural Guatemala. Aug. 1990. 50 p. (Unpublished).
(170.) RAHMAN, M., KHAN, M.A., CALDWELL, B.K., and KANE, T.T. Factors associated with reported side-effects of oral pills and injectibles in rural Bangladesh. In: Kane, T.T., Barkat-e-Khuda, and Phillips, J.R, eds. Reproductive Health in Rural Bangladesh: Policy and Programmatic Implications. Vol. 1. Dhaka, International Centre for Diarrhoeal Disease Research, Bangladesh. Jul. 1997. p. 191-216.
(171.) RAMSAY, S. UK “pill scare” led to abortion increase. Lancet 347(9008): 1109. Apr. 20, 1996.
(172.) RANDLE, N. Antibiotic- and anticonvulsant-induced oral contraceptive failure. Journal of Pharmacy Technology 1(6): 246-249. Nov./Dec. 1985.
(173.) REANEY, P. Half of UK women seeking abortion used contraception. (London). Reuters wire service. Nov. 13, 1999.
(174.) REES, H. Acquiring the pill: Safety issues. Reproductive Health Matters (3): 41-45. May 1994.
(175.) RINEHART, W., RUDY, S., and DRENNAN, M. GATHER guide to counseling. Population Reports, Series J, No. 48. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Dec. 1998. 32 p.
(176.) ROSENBERG, M. (Health Decisions, Inc.) [Factors related to DC use] Personal communication, May 2000.
(177.) ROSENBERG, M. [Length of oral contraceptive use] Personal communication, Dec. 1999.
(178.) ROSENBERG, M. and WAUGH, M.S. Causes and consequence of oral contraceptive noncompliance. American Journal of Obstetrics and Gynecology 180(2, Pt. 2): S276-S279. Feb. 1990.
(*)(179.) ROSENBERG, M.J., BURNHILL, M.S., WAUGH, M.S., GRIMES, D.A., and HILLARD, P.J. Compliance and oral contraceptives: A review. Contraception 52(3): 137-141. Sep. 1995.
(180.) ROSENBERG, M.J. and WAUGH, M.S. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. American Journal of Obstetrics and Gynecology 179(3, Pt. 1): 577-582. Sep. 1998.
(*)(181.) ROSENBERG, M.J., WAUGH, M.S., and LONG, S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. Journal of Reproductive Medicine 40(5): 355-360. May 1995.
(182.) ROSENBERG, M.J., WAUGH, M.S., and MEEHAN, T.E. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation. Contraception 51(5): 283-288. May 1995.
(183.) ROSENFIELD, A.G. and LIMCHAROEN, C. Auxiliary midwife prescription of oral contraceptives: An experimental project in Thailand. In: Foreit, J.R. and Frejka, T., eds. Family Planning Operations Research: A Book of Readings. New York, Population Council. 1998. p. 71-81.
(*)(184.) ROSS, J. Contraception: Short-term vs. long-term failure rates. Family Planning Perspectives 21(6): 275-277. Nov./Dec. 1989.
(185.) SALTER, C., JOHNSTON, H.B., and HENGEN, N. Care for postabortion complications: Saving women’s lives. Population Reports, Series L, No. 10. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Sep. 1997. 32 p.
(186.) SAMBISA, W. Contraceptive use dynamics in Zimbabwe: Discontinuation, switching, and failure. Calverton, Maryland, Macro International, Dec. 1996. (Zimbabwe Further Analysis) 24 p.
(187.) SAMUELS, S.E., STRYKER, J., and SMITH, M.D. Over-the-counter birth control pills: An overview. In: Samuels, S.E. and Smith, M.D., eds. The Pill: From Prescription to Over the Counter. Menlo Park, California, Kaiser Family Foundation. 1994. p. 1-19.
(188.) SCHAEFER, L. (Performance Improvement Consultative Group, JHPIEGO representative) [Revised definition of performance improvement] Personal communication, May 12, 2000.
(189.) SCHONDELMEYER, S.W. and JOHNSON, J.A. Economic implications of switching from prescription status. In: Samuels, S.E. and Smith, M.D., eds. The Pill: From Prescription to Over the Counter. Menlo Park, California, Kaiser Family Foundation. 1994. p. 189-235.
(190.) SCHULER, S.R. and HOSSAIN, Z. Family planning clinics through women’s eyes and voices: A case study from rural Bangladesh. International Family Planning Perspectives 24(4): 170-175, 205. Dec. 1998. (Available: http://www.agi-usa.org/pubs/journals/ 2417098.html)
(191.) SEALZA, L. Factors affecting the family planning program drop-out rate in Bukidnon, Philippines. Manila, Research Institute for Mindanao Culture and Population Council, 1994.81 p.
(192.) SEKADDE-KIGONDU, C., MWATHE, E.G., RUMINJO, J.K., NICHOLS, D., KATZ, K., JESSENCKY, K., and LIKU, J. Acceptability and discontinuation of Depo-Provera, IUCD and combined pill in Kenya. East African Medical Journal 73(12): 786-794. Dec. 1996.
(193.) SERFATY, D. Medical aspects of oral contraceptive discontinuation. Advances in Contraception 8(Suppl. 1): 1-76. Oct. 1992.
(194.) SERFATY, D. Oral contraceptive compliance during adolescence. In: Creatsas, G., Mastorakos, G., and Chrousous, G.P., eds. Adolescent Gynecology and Endocrinology: Basic and Clinical Aspects. Annals of the New York Academy of Sciences. Vol. 816. Athens, Greece, New York Academy of Sciences. Jun. 17, 1997. p. 422-431.
(195.) SHAIN, R.N. and POTTS, M. Need for and acceptability of long-acting steroidal contraception. In: Zatuchni, G.L., Goldsmith, A., Shelton, J.D., and Sciarra, J.J., eds. Long-Acting Contraceptive Delivery System. Philadelphia, Harper and Row. 1984. p. 1-19.
(196.) SHANE, B. and CHALKLEY, K. From research to action: How operations research is improving reproductive health services. Washington, D.C., Population Reference Bureau, Mar. 1998. 40 p.
(197.) SHELTON, J.D. Precise pill-taking “behavior.” Jim Shelton’s Pearls (Website). http://www.jhuccp.org/pearls/September99/sept 399.stm. 1999.
(198.) SHELTON, J.D., ANGLE, M.A., and JACOBSTEIN, R.A. Medical barriers to access family planning. Lancet 340(8831): 1334-1335. Nov. 28, 1992.
(*)(199.) SHELTON, J.D., DAVIS, S., and MATHIS, J. Checklist for family planning service delivery, with selected linkages to reproductive health: Maximizing access and quality [brochure]. US Agency for International Development, 1998.20 p.
(*)(200.) SHELTON, J.D. and DAVIS, S.S. Some priorities in maximizing access to and quality of contraceptive services. Advances in Contraception 12(3): 233-237. Sep. 1996.
(201.) SHENFIELD, G.M. Oral contraceptives: Are drug interactions of clinical significance? Drug Safety 9(1): 21-37. 1993.
(202.) SHENFIELD, G.M. and GRIFFIN, J.M. Clinical pharmacokinetics of contraceptive steroids: An update. Clinical Pharmacokinetics 20(1): 15-37. Jan. 1991.
(203.) SMITH, S.K., KIRKMAN, R.J., ARCE, B.B., MCNEILLY, A.S., LOUDON, N.B., and BAIRD, D.T. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalmic-pitutitary-ovarian axis. Contraception 34(5): 513-522. Nov. 1986.
(204.) SOBTI, J.C., RAO, A.R., DEERING, J., and SHAH, I.C. Project report on the involvement of Indian Medical Association members for promoting oral contraceptive pill and IUCD in Gujarat. Training of 1326 family planning counselors and 83 family planning consultants. New Delhi, IMA-AKN Sinha Institute of Continuing Medical and Health Education and Research, 1995. 64 p.
(205.) SOLO, J. and BILLINGS, D.L Linkages with treatment for incomplete abortions improve family planning services in Kenya. Operations Research Alternatives, Washington, D.C. Population Council, Aug. 1998. p. 3. (Available: http://www.popcouncil.org/r hfp/alternatives/linkages.html)
(206.) SPARROW, M.J. Pregnancies in reliable pill takers. New Zealand Medical Journal 102(879): 575-577. Nov. 8, 1989.
(207.) SPARROW, M.J. Pill method failures in women seeking abortion: Fourteen years experience. New Zealand Medical Journal 111(1075): 386-388. Oct. 9, 1998.
(208.) STANBACK, J., QURESHI, Z., SEKADDE-KIGONDU, C., GONZALEZ, B., and NUTLEY, T. Checklist for ruling out pregnancy among family-planning clients in primary care. Lancet 354(9178): 566. Aug. 14, 1999.
(209.) STANBACK, J., THOMPSON, A., HARDEE, K., and JANOWITZ, B. Menstrual requirements: A significant barrier to contraceptive access in developing countries. Studies in Family Planning 28(3): 245-250. Sep. 1997.
(210.) STANG, A., Schwingl, P., and Rivera, R. New contraceptive eligibility checklists for combined oral contraceptives (COCs) and depot-medroxyprogesterone acetate (DMPA) provision in community-based services programmes. Bulletin of the World Health Organization 78(5). May 2000.
(211.) STARRS, A. The safe motherhood action agenda: Priorities for the next decade. Inter-Agency Group for Safe Motherhood, 1998. 98 p.
(212.) STEWART, M. Many pill users in Egypt lack adequate knowledge about how to take the pill. International Family Planning Perspectives 21(3): 123-124. Sep. 1995.
(213.) STONE, S.C. Should oral contraceptives be sold over-the-counter? American Journal of Gynecologic Health 7(2): 27-32. Var./Apr. 1993.
(214.) STOREY, D., BOULAY, M., KARKI, Y., HECKERT, K., and KARMACHARYA, D.M. Impact of the integrated Radio Communication Project in Nepal, 1994-1997. Journal of Health Communication 4: 271-294. 1999.
(215.) SULLIVAN, R., BRECHIN, S., and LACOSTE, M. Structured on-the-job training: Innovations in international health training. In: American Society for Training and Development (ASTD), ed. Linking HRD Programs with Organizational Strategy. ASTD. p. 155-179. (Available: http://www.reproline.jhu.edu/english/3improve/3 ojt/ojt1.htm)
(216.) SULLIVAN, H., FURNISS, H., SPONA, J., and ELSTEIN, M. Effect of 21-day and 24-day DC regimens containing gestodene (60 [micro]g) and ethinyl estradiol (15 [micro]g) on ovarian activity. Fertility and Sterility 72(1): 115-120. Jul. 1999.
(217.) SUYONO, H., HENDRATA, L., and ROHDE, J. The family planning movement in Indonesia. In: Rohde, J., Chatterjee, M., and Morley, D., eds. Reaching Health for All. New Delhi, Oxford University Press. 1993. p. 482-500.
(218.) SZAREWSKI, A. and GUILLEBAUD, J. Contraception: A User’s Handbook. Oxford, Oxford University Press, 1994. 264 p.
(219.) TAYOB, Y., ROBINSON, G., ADAMS, J., NYE, M., WHITELAW, N., SHAW, R.W., JACOBS, H.S., and GUILLEBAUD, J. Ultrasound appearance of the ovaries during the pill-free interval. British Journal of Family Planning 16(3): 94-96. Oct. 1990.
(220.) TECHNICAL GUIDANCE/COMPETENCE WORKING GROUP. Recommendations for updating selected practices in contraceptive use, Volume I. Curtis, K.M. and Bright, P.L., eds. US Agency for International Development, World Health Organization, Nov. 1994.130 p. (Available: http://www.reproline.jhu.edu/e nglish/6read/6multi/6tgwg/6tgwg.htm, Accessed Aug. 10, 1999)
(221.) TECHNICAL GUIDANCE/COMPETENCE WORKING GROUP. Recommendations for updating selected practices in contraceptive use, Volume II. Gaines, M., ed. US Agency for International Development, World Health Organization, Sep. 1997. 260 p. (Available: http://www.reproline.jhu.edu/english/6re ad/6multi/6tgwg/6tgwg.htm, Accessed Aug. 10, 1999)
(222.) TOWNSEND, S. Attitudes, regulations hinder use of the pill. Network 13(3): 6-10. Research Triangle Park, North Carolina, Family Health International. Mar. 1993.
(223.) TRUSSELL, J. Contraceptive efficacy. In: Hatcher, R., Trussell, J., Stewart, F., Cates Jr., W., Stewart, G.K., Guest, F., and Kowal, D., eds. Contraceptive Technology. 17th ed. New York, Ardent Media. 1998. p. 779-791.
(224.) TRUSSELL, J., STEWART, F., POTTS, M., GUEST, F., and ELLERTSON, C. Should oral contraceptives be available without prescription? American Journal of Public Health 83(8): 1094-1099. Aug. 1993.
(225.) TRUSSELL, J. and VAUGHAN, B. Contraceptive failure, method-related discontinuation and resumption of use: Results from the 1995 National Survey of Family Growth. Family Planning Perspectives 31(2): 64-72, 93. Var./Apr. 1999. (Available: http://www.agi-usa.org/pubs/journals/3106499.html)
(226.) TSUI, A.D. and OCHOA, L.H. Service proximity as a determinant of contraceptive behavior: Evidence from cross-national studies of survey data. Chapel Hill, North Carolina, Carolina Population Center, Mar. 1989. (Carolina Population Center Papers No. 89-05) 43 p.
(*)(227.) TWEEDIE, I., OFORI, J., and GLASS, W. Family planning continuation among MOH defaulters in Ghana. Baltimore, Ghana Ministry of Health/Health Education Unit, and Johns Hopkins School of Public Health Center for Communication Programs, Apr. 1996.38 p. (Draft preliminary report).
(228.) TWUM-BAAH, K.A. and STANBACK, J. Provider rationales for restrictive family planning service practices in Ghana [Fact sheet]. Ghana Statistical Service, Family Health International, Nov. 1996. 3 p.
(229.) UNITED NATIONS FUND FOR CHILDREN (UNICEF). WHO/UNICEF/UNFPA workshop on systematizing experiences in implementing women-friendly health services. UNICEF (Website). http:/www.unicef.org/safe/Jan.26-28, 1999. (Executive summary report)
(230.) US FOOD AND DRUG ADMINISTRATION. FDA to hold public meeting on regulation of OTC products. (Website). http:// www.fda.gov/bbs/topics/NEWS/NEW00725.html. Apr. 27, 2000.
(231.) WAHAB, M. and KILLICK, S. Oral contraceptive knowledge and compliance in young women. British Journal of Family Planning 22(4): 170-174. Jan. 1997.
(232.) WANG, C.C., VITTINGHOFF, E., HUA, L.S., YUN, W.H., and RONG, Z.M. Reducing pregnancy and induced abortion in China: Family planning with husband participation. American Journal of Public Health 88(4): 646-648. Apr. 1998.
(233.) WANG, E., SHI, S., CEKAN, S.Z., LANDGREN, B.M., and DICZFALUSY, E. Hormonal consequences of “missing the pill.” Contraception 26(6): 545-565. Dec. 1982.
(*)(234.) WEAVER, K. and GLASIER, G. Interaction between broadspectrum antibiotics and the combined oral contraceptive pill: A literature review. Contraception 59(2): 71-78. Feb. 1999.
(235.) WEISBERG, E. OCs and community failure rate: What can the GP do to reduce it? Current Therapeutics 35(9): 47-48, 51-52. Sep. 1994.
(236.) WELLS, E., CROOK, B., and MULLER, N. Emergency contraception: A resource manual for providers. Seattle, Washington, Program for Appropriate Technology in Health, May 1997.34 p.
(237.) WESTCOTT, M., KOVACS, G., and JARMAN, H. Attitudes to oral contraception in family planning attenders. British Journal of Family Planning 18(3): 85-88. Oct. 1992.
(238.) WESTOFF, C.F. and BANKOLE, A. Mass media and reproductive behavior in Africa. Calverton, Maryland, Macro International, Apr. 1997. (Demographic and Health Surveys Analytical Report No. 2) 39 p.
(239.) WESTOFF, C.F. and BANKOLE, A. Mass media and reproductive behavior in Pakistan, India and Bangladesh. Calverton, Maryland, Macro International, May 1999. (Demographic and Health Surveys Analytical Report No. 10) 32 p.
(240.) WILLIAMS-DEANE, M. and POTTER, L.S. Current oral contraceptive use instructions: An analysis of patient package inserts. Family Planning Perspectives 24(3): 111-115. May/Jun. 1992.
(241.) WINIKOFF, B. Extra contraceptive protection during combined oral contraceptive use and antibiotics. In: Weaver, K. and Glasier, A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. Contraception 59(2): 71-78. 1999.
(242.) WOOD, R., BOTTING, B., and DUNNELL, K. Trends in conceptions before and after the 1995 pill scare. Office for National Statistics, United Kingdom, Autumn, 1997. 89 p.
(243.) WORLD HEALTH ORGANIZATION (WHO). Abortion. A tabulation of available data on the frequency and mortality of unsafe abortion. Geneva, WHO, 1997.
(*)(244.) WORLD HEALTH ORGANIZATION (WHO). Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. Geneva, WHO, 1996. 143 p.
(*)(245.) WORLD HEALTH ORGANIZATION (WHO). Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. 2nd ed. Geneva, WHO, May 2000. (Draft).
(246.) WORLD HEALTH ORGANIZATION (WHO) and INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO). Community-based services for family planning: The role of the medical profession. International journal of Gynecology and Obstetrics 49(1): 85. Apr. 1995.
(247.) YESHAYA, A., ORVIETO, R., KAPLAN, B., BAR-HAVA, I., BAR, J., and BEN-RAFAEL, Z. Flexible starting schedule for oral contraception: Effect on the incidence of breakthrough bleeding and compliance. European Journal of Contraception and Reproductive Health Care 3(3): 121-123. Sep. 1998.
(248.) YESHAYA, A., ORVIETO, R., KAUSCHANSKY, A., DICKER, D., BAR-HAVA, I., and BEN-RAFAEL, Z. A delayed starting schedule of oral contraception: The effect on the incidence of breakthrough bleeding and compliance in women. European Journal of Contraception and Reproductive Health Care 1 (3): 263-265. Sep. 1996.
(249.) YOUNGKIN, E.Q., DAVIS, M.S., and KOLB, K.W. Making oral contraceptives available over-the-counter [letter]. Nurse Practitioner 21(3): 13, 133-134, 143-144. Mar. 1996.
(250.) ZAVALA, A.S., PEREZ-GONZALES, M., MILLER, P., WELSH, M., WILKINS, L.R., and POTTS, M. Reproductive risks in a community-based distribution program of oral contraceptives, Matamoros, Mexico. Studies in Family Planning 18(5): 284-290. Sep./Oct. 1987.
(251.) BELFIELD, T. (Family Planning Association (UK)) [Practical use of seven-day guidelines] Personal communication, Jun. 16, 2000.
(252.) GESTODENE STUDY GROUP 324. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60[micro]g/ethinlyestradiol 15[micro]g and a 21 .day regimen of desogestrel 150[micro]g/ethinylestradiol 20[micro]g. European Journal of Contraception and Reproductive Health Care 4(Suppl. 2): 17-25. Nov. 1999.
(253.) HANSEN, T.H. and LUNDVALL, F. Factors influencing the reliability of oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica 76(1): 61-64. Jan. 1997.
(254.) KAKOURIS, H. and KOVACS, G.T. Pill failure and non-use of secondary precautions. British Journal of Family Planning 18(2): 41-44. Jul. 1992.
(255.) KOVACS, G.T., RIDDOCH, G., DUNCOMBE, P., WELBERRY, L., CHICK, P., and WEISBERG, E. Inadvertent pregnancies in oral contraceptive users. Medical Journal of Australia 150(10): 549-551. May 15, 1989.
(256.) PSL GROUP. Minesse (Gestodene/Ethinyl Estradiol), low-dose contraceptive, approved in Europe. Doctor’s Guide. Mar. 23, 2000. (Available: http://www.pslgroup.com/dg/19396e.htm)
(257.) WORLD HEALTH ORGANIZATION (WHO). Overcoming antimicrobial resistance. Geneva, WHO, 2000.
(258.) YIMIN, C., WEI, Z., ZHIMIN, L., YANG, Z., and AIYING, W. Contraceptive practices of women requesting termination of pregnancy: A study from China. Contraception 55(1): 15-17. Jan. 1997.
(259.) YOUNG, LK., FARQUHAR, C.M., MCCOWAN, L.M., ROBERTS, H.E., and TAYLOR, J. The contraceptive practices of women seeking termination of pregnancy in an Auckland clinic. New Zealand Medical Journal 107(978): 189-192. May 25, 1994.
COPYRIGHT 2000 Department of Health
COPYRIGHT 2004 Gale Group